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Magdalena J Kiprowska
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ABSTRACT

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive
neuronal loss that over the years spreads from the hippocampus to the neural cortex and impairs
memory and cognitive functions. At the cellular level AD is linked to the presence of β-amyloid
plaques and neurofibrillary tangles but despite decades of research little is known about their
contribution to neurodegeneration and whether they are a cause or rather a result of the disease. It
is well established that proteasome activity is impaired in AD brains and some studies suggest that
this could be one of the initial factors leading to development of this disorder. Defective ubiquitin
proteasome pathway (UPP) leads to accumulation of truncated or misfolded, ubiquitinated proteins
(Ub-proteins) that can further form insoluble aggregates such as β-amyloid plaques and
neurofibrillary tangles. The UPP involves a multitude of components and steps. It starts with the
v

ATP-dependent E1, E2 and E3 enzymatic cascade that results in tagging targeted proteins with
polyubiquitin chains. Subsequently, shuttling factors recognize and deliver tagged proteins to the
proteasome for degradation. Once at the proteasome, deubiquitinating enzymes (DUBs) remove
the polyubiquitin chain and still other proteasome subunits are involved in unfolding and
translocating the targeted protein into the degradation chamber where it is cleaved into small
peptide fragments. Several components of this pathway were shown to be dysregulated in
neurodegenerative disorders. It has been recognized that enhancing UPP activity could be of
therapeutic benefit as it would prevent or diminish accumulation of toxic proteins and possibly
prevent neuronal death.
The major GOAL of our studies was to investigate two new potential therapeutic targets
for AD related to UPP function:
a) The Usp14 deubiquitinating enzyme – we investigated whether its inhibition
increases proteasome-dependent degradation and decreases toxicity induced by the
endogenous product of inflammation PGJ2.
b) The product of inflammation PGJ2 that impairs different steps of the UPP – we
investigated whether PGJ2 induces AD-like neuronal and behavioral pathology in vivo, by
microinfusing PGJ2 into hippocampi of young and old mice. In addition, we determined
the potential of PACAP to overcome the deleterious effects of PGJ2.
a) Studies with Usp14: Usp14 is a deubiquitinating enzyme that decreases proteasomedependent degradation rates of certain substrates by removing their polyubiquitin chain before the
substrate is committed to degradation. This leads to premature dissociation of the substrate from
the proteasome thus escaping degradation altogether. A recent study showed that downregulating
vi

Usp14 leads to increased degradation of known proteasome substrates implicated in
neurodegenerative diseases, such as Tau, TDP-43 and ataxin-3. In addition, IU1 (1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone) is a selective Usp14 inhibitor
that was shown to increase proteasome-dependent degradation rates and could serve as a potential
therapeutic. These studies were conducted with the HEK (human embryonic kidney) cell line and
murine embryonic fibroblasts (MEFs), and not with primary neurons.
We investigated the therapeutic potential of targeting Usp14 with IU1 in a more relevant
cell model for AD, which is rat E18 cerebral cortical neuronal cultures. The results of our studies
were most unexpected. We established that IU1 treatment indeed diminishes the levels of
polyubiquitinated proteins but not due to enhanced proteasome-dependent degradation. Instead
IU1 prevented the formation of polyubiquitin chains. IU1 blocked mitochondrial complex 1 which
resulted in mitochondrial impairment and drastically lowered ATP levels. Such low levels of ATP
are insufficient to activate the E1 enzyme of the ubiquitination cascade. E1 carries-out the first
step that is responsible for activating ubiquitin. By assessing E1~Ub thioester formation, we
confirmed that IU1-treatment lowers E1 activity resulting in low levels of Ub-proteins. Initially it
may have appeared that IU1 treatment indeed sped up protein clearance by the proteasome.
However, our observation that IU1-treatment lowered 26S proteasome levels with a concomitant
increase in 20S proteasomes, suggested that there was not enough ATP in the cell to assemble 26S
proteasomes and ensure their optimal activity.
Overall, we showed that IU1, a potential therapeutic that was intended to prevent the
accumulation of ubiquinated proteins, did not increase proteasome-dependent degradation.
Instead, IU1-treatment blocked the ubiquitination cascade by inhibiting the mitochondrial complex
1 and depleting ATP levels.
vii

Our additional studies demonstrated that downregulating Usp14 with siRNA in rat cortical
cultures, or Usp14 loss in cortical cultures from Usp14axJ mice, did not improve the rates of Ubprotein degradation. Our results are of high importance to the development of potential
therapeutics that target the UPP because of its relevance to AD.
b) Studies with the product of inflammation PGJ2: Although UPP impairment has been
linked to the development of AD, it is still not known what triggers it. Studies point to chronic
neuroinflammation as a major contributing factor. Traumatic brain injury (TBI) and stroke both
induce neuroinflammation and increase the probability of developing AD. Chronic
neuroinflammation, as opposed to its acute version, wreaks havoc in the cells, perpetuating the
cycle of synthesis of toxic prostaglandins and continual activation of pathways that lead to
neuronal demise. Prostaglandin J2 (PGJ2) is an endogenous product of inflammation and is
released by activated microglia, astrocytes and neurons as a part of the immune response. Previous
work from our lab confirmed that PGJ2 is the most toxic of the prostaglandins tested and induces
AD-relevant neuropathological changes at the molecular and cellular levels. Firstly, PGJ2 activates
caspase-3 and leads to caspase-3-dependent Tau cleavage at Asp421, which leads to formation of
aggregation prone ΔTau, the major component of neurofibrillary tangles. Secondly, PGJ2 leads to
the accumulation and aggregation of ubiquitinated proteins in plaques and tangles, which are AD
hallmarks. Thirdly, PGJ2 perturbs the UPP (a) by causing 26S proteasome dissociation of the
regulatory and core particles due to carbonylation of the Rpt5 subunit, thus decreasing the levels
of 26S proteasomes, and (b) by inhibiting DUBs such UCHL-1. PGJ2 can exert its function via
two mechanisms. The first mechanism involves covalent modification of exposed cysteine
residues in proteins leading to the formation of Michael adducts. The second mechanism is
mediated by receptor binding, including the DP2 and PPARγ receptors.
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PGJ2 is a product of the pro-inflammatory enzymes cyclooxygenases, including
cyclooxygenase-2 (COX-2), the levels of which increase in AD brains and negatively affect
neuronal function. COX-2 catalyzes the synthesis of prostaglandins, some of which are
neuroprotective while others are neurotoxic. Treatment with non-steroidal anti-inflammatory
drugs (NSAIDs), which target cycloxygenases, is one of the therapeutic strategies aimed at
minimizing neuroinflammation. However, this anti-inflammatory strategy can produce adverse
effects, including renal failure, heart attack and stroke, as well as preventing the synthesis of
neuroprotective prostaglandins. Therefore, identifying a therapeutic target that is downstream of
cyclooxygenases would be beneficial to prevent the effects of neurotoxic prostaglandins, without
interfering with the neuroprotective ones. Targeting PGJ2, shown to induce AD-like pathology in
cerebral cortical neuronal cultures, could offer a better strategy to prevent inflammation-dependent
neurotoxicity.
We investigated whether or not PGJ2 elicits AD-like pathology in vivo by injecting it into
the CA1 hippocampal brain region in mice. Since aging is a major risk factor in sporadic AD (sAD)
we treated old (52 weeks of age) and young (12 weeks of age) mice to determine if advanced age
can make them more susceptible to PGJ2-linked toxicity. Our studies revealed that PGJ2 impairs
learning and memory retention in old but not in young mice as assessed with the radial 8-arm maze
(RAM) test. Additionally, PGJ2 induced neurodegeneration that spanned from the CA1 to the CA3
hippocampal region in old but not young mice. Lastly we investigated the levels of dendritic spines
as their increased numbers are associated with learning and memory. However, the decrease in
dendritic spine levels is linked to memory impairment associated with neurodegeneration. We
showed that PGJ2-treatment induced dendritic spine changes in old but not in young mice.
Compared to young mice, old mice displayed significantly less plastic, immature spines associated
ix

with learning, which could explain their poor performance during the RAM test. Therefore, our in
vivo studies showed that PGJ2 hippocampal injections induced AD-like symptoms and pathology
in the mice.
Lastly, we co-injected the group of old mice (53 weeks of age) with PGJ2 and PACAP27
to determine if some of the PGJ2-induced pathological symptoms could be prevented. PACAP is
a neuroprotective peptide that acts through activation of the cAMP/PKA pathway. PACAP is
abundant in the brain and its levels decrease during neurodegeneration. We subjected the mice to
RAM training and found learning improvement in mice co-administered PGJ2+PACAP compared
to mice treated with PGJ2 alone, although this change was not statistically significant. These
results indicate that PGJ2 is indeed an effective therapeutic target, and that targeting PGJ2 to
prevent/treat AD could potentially be more efficient than targeting COX-2.
In conclusion, we investigated two potential therapeutic approaches for AD: a) increasing
UPP activity, and b) preventing inflammation-based toxicity by focusing on PGJ2, a product of
cyclooxygenases. Our studies showed that IU1 is not an effective therapeutic for neurons due to
its off-targeting effects on mitochondrial complex 1. Moreover, genetically downregulating Usp14
is not sufficient to induce significant changes in proteasome-dependent degradation rates. Perhaps
combining this strategy with another neuroprotective therapeutic or peptide, such as PACAP,
would improve the results. Lastly, we showed that PGJ2 by itself induces AD-like pathology in
vivo that could be partially prevented by PACAP. PGJ2 could be a better and more directed
therapeutic target than COX-2, to halt the deleterious effects of neuroinflammation with fewer side
effects.
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CHAPTER I

INTRODUCTION

Therapeutic targets for Alzheimer’s Disease: Ubiquitin/Proteasome Pathway and
the endogenous product of inflammation prostaglandin J2

Magdalena J Kiprowska

Department of Biological Sciences,
Hunter College of the City University of New York,
New York, New York 10065
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1.1.

ABSTRACT
Interfering with the UPP has recently provided a promising therapeutic approach for

treatment of numerous disorders including neurodegenerative diseases. Targets are varied and
include the proteasome, E1, E2 and E3 enzymes as well as many DUBs. Some of the therapeutics
directed at the proteasome, usually targeting the β5 and/or β1 subunits, have even found their way
into clinical trials in cancer therapy, like carfilzomib (Phase III against relapsed multiple
myeloma), MLN9708 (Phase I), CEP18770 (Phase I) and the natural product NPI-0052 (Phase I).
The UPP is involved in maintaining cellular homeostasis at several levels, like regulating cell cycle
progression, apoptosis, various signaling pathways and finally removal of dysfunctional proteins.
Abnormalities in any of the steps involved in the cascade of events leading to proteasomedependent degradation result in different disorders so the targets vary. With respect to
neurodegenerative diseases that result from abnormal accumulation of toxic proteins it would be
beneficial to aim at a factor that would preserve or enhance proteasome function. Targeting Usp14
seems to be a promising therapeutic strategy in AD, since inhibiting the deubiquitinating activity
of Usp14 in different cell lines results in increased degradation of several proteins including Tau
which is relevant to AD. Usp14 exhibits ubiquitin chain trimming activity that can lead to the
dissociation of protein substrates from the proteasome, if the ubiquitin removal is faster than the
competing steps leading to substrate degradation. The finding that Usp14 inhibition results in
increased degradation of Tau, the accumulation and aggregation of which is strongly associated
with AD pathology seems to be a very interesting prospect that has to be investigated further in
primary neuronal cultures. Inhibition of Usp14 was achieved with the small molecule inhibitor
IU1: 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone [101]. IU1
seems to act selectively toward Usp14 and to increase degradation of numerous proteasomal
2

substrates, like cyclin B or TDP-43 presumably by inhibiting chain trimming activity thus
preventing proteins targeted for degradation from premature dissociation from the proteasome.
Our studies established that high concentrations of IU1 (HIU1, 75µM) reduce the accumulation of
Ub-proteins induced by the endogenous product of inflammation, prostaglandin J2 (PGJ2) in
primary neuronal cultures while low IU1 concentrations (25µM) had no effect. Additionally, we
showed that treatment with HIU1 resulted in (a) decrease in ATP levels, (b) a decline in 26S
proteasome activity and levels with a concomitant increase in 20S proteasome, (c) calpain
activation and calpain-mediated Tau cleavage. These data suggested that apart from the presumed
effect on proteasomal degradation rates, IU1 also affects mitochondria. This was confirmed by
testing mitochondrial respiratory chain complex activities which revealed that IU1 specifically
inhibits complex I thus leading to overall cellular demise. Investigating mechanisms by which
potential therapeutics, like IU1 act on neuronal homeostasis, contributes to AD-relevant
therapeutic research.

Figure 1. Ubiquitination and degradation of
proteins by the ubiquitin/proteasome pathway
(UPP). Protein ubiquitination is a complex ATPdependent process in which ubiquitin (Ub) is
sequentially activated by ubiquitin-activating
enzymes (E1), transferred to ubiquitinconjugating enzymes (E2) and ligated to protein
substrates by ubiquitin ligases (E3). Polyubiquitin
chains are formed by isopeptide bonds between
Gly76 and Lys48 on adjacent ubiquitin molecules.
Once a protein is polyubiquitinated, it is degraded
rapidly by the 26S proteasome. Deubiquitinating
enzymes (DUB) remove and disassemble
polyubiquitin chains (scheme by Dr. Vita Vernace, a
former PhD student in the Pereira lab).
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1.2.

THE UBIQUITIN-PROTEASOME PATHWAY
The UPP requires most proteins to be tagged by ubiquitin to target them for degradation.

Proteolysis by the UPP involves two major steps: ubiquitination and degradation (Figure 1). A deubiquitination step also plays important role in this pathway as it edits the ubiquitination state of
proteins and removes the ubiquitin tag for recycling. Our studies were aimed at increasing 26S
proteasome-dependent degradation rates.
The 26S Proteasome: Covalent binding of
ubiquitin to proteins marks them for degradation
by the ubiquitin/ATP dependent proteinase known
as

the

26S

proteasome.

The

latter

is

a

multicomponent enzymatic complex with a native
molecular mass of approximately 2000kDa [22].
Figure 2. The 26S proteasome. Its two major
particles, the 20S particle (20S proteasome) which
is the catalytic core and the 19S particle (PA700)
which is the regulatory component, require ATP
binding to assemble into the 26S proteasome. The
crystal structure of the 20S proteasome was
obtained from (Groll et al., 1997)

The 26S proteasome complex is composed of two
major particles (Figure 2): (1) A cylinder-like
structure, known as the 20S proteasome that is
located in the center and comprises the proteolytic
core of the enzyme, and (2) a regulatory component

known as the 19S particle (PA700), which may be attached to each end of the cylinder-like 20S
proteasome (reviewed in [33]).
The 19S particle is a multicomponent complex itself containing at least 17 subunits and
can be further divided into two subcomplexes: the base and the lid. The base confers ATPase
activity and consists of six AAA ATPase subunits (Rpt1-Rpt6) and two non-ATPase subunits
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(Rpn1 and Rpn2). The lid is made up of eight non-ATPase subunits (Rpn3, Rpn5-9, Rpn11, and
Rpn12) which can specifically bind polyubiquitin-tagged substrates and also deubiquitinate them
[33]. Rpn10 helps to tether the lid and the base, and is a receptor for polyubiquitinated substrates
[59,59].
The eukaryotic 20S proteasome consists of 28 subunits, which are arranged in four
heptameric stacked rings forming a barrel-like structure, each consisting of 7 protein subunits. The
-type subunits, comprising the two outer rings of the 20S proteasome, provide binding sites for
regulatory particles and form a gated channel leading to the inner proteolytic chamber. The -type
subunits contain the active sites of the 20S proteasome. The whole particle is a dimer with an
7777 subunit arrangement (reviewed in [33]).
The 20S particle may be alternatively capped by other complexes, including the 11S
activator (PA28). PA28 is a cytoplasmic complex formed by equal, stoichiometric amounts of two
different 28 kDa subunits, PA28α and PA28β, forming a 200 kDa heterohexamer. PA28 capped
20S proteasomes prefer substrates that are partially degraded proteins and peptides, rather than
intact polyubiquitinated molecules [37,61].
Proteasome Assembly: The 19S particle guides proteins into the 20S proteasome chamber where
unfolded proteins are degraded into short peptides (of 8-9 amino acids). Association between the
19S RP and 20S CP is a dynamic process and requires ATP binding [112]. During degradation of
one substrate molecule by the 26S proteasome, it was calculated that 300–400 ATP molecules are
hydrolyzed. Substrate binding activates ATP hydrolysis, which promotes three processes:
substrate unfolding, gate opening in the 20S particle, and protein translocation [9]. ATP binding
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is necessary for the rapid association/dissociation of the 26S proteasome from/into the 19S particle
and 20S proteasome [4].
Multiple assembly chaperones are required in different stages of proteasome assembly.
During 20S proteasome assembly in mammalian cells, PAC1-PAC4 (Proteasome assembly
chaperone 1-4) bind to early-assembly intermediates of proteasome α-subunits and promote α-ring
formation [158]. Specifically, the PAC1-PAC2 heterodimer remains attached to the nascent α-ring
and suppresses premature α-ring dimerization, thereby promoting attachment of β-subunits to the
proper surface of the α-ring. The PAC3-PAC4 complex then dissociates from the α-ring due to
steric hindrance with the β3 subunit [73]. The following steps require the assistance of another
chaperone, POMP (proteasome maturation protein). POMP inhibits the premature β-ring
dimerization until the β7 subunit is properly incorporated [106]. In yeast, it is found that these
premature complexes are in association with proteasome activators (PA), either Blm10 (ortholog
of human PA200), or with the 19S RP (PA700) [151]. Dimerization of two half-proteasomes is
triggered by incorporation of the β7 subunit, which stabilizes the nascent proteasome via its long
C-terminal extension together with Blm10. Subsequently, with the autocatalytic maturation of βsubunits, the nascent 20S proteasome is activated, leading to degradation of POMP and PAC1PAC2. Mature 20S proteasomes function as templates for the initial assembly of the 19S RP.
Compared with 20S proteasome assembly, little is known about the mechanism of 19S RP
assembly. The RP is subdivided into lid and base subcomplexes. A recent study [51] demonstrated
the role of four conserved assembly factors in the yeast RP base assembly, including Hsm3
(ortholog of human S5b), Nas2, Nas6, and Rpn14. These chaperones interact directly with Rpt1Rpt6 (Proteasome regulatory particle 1-6) subunits. Nas2 is released after the base precursor is
formed. The addition of Rpn10 and the lid contributes to the formation of the RP precursor. Later,
6

the three other chaperones, Hsm3, Nas6 and Rpn14, are released when 20S CP associates with RP
precursors.
As for 26S proteasome assembly, two proteins were proposed to facilitate this process:
Blm10 and Nob1. Blm10/PA200, a 200 kDa α-helix-rich repeat protein, is found attached to the
20S α-surface and apparently activates some proteolytic properties by gating the entrance pore
[144,164] [83]. Nob1, a nuclear protein in yeast present only during the cell-growing phase,
associates with the 19S RP and is degraded just after the doubly capped 26S proteasome is [189].
It is suggested that Nob1 might be required for the nuclear translocation of the 20S [159].
The Three Peptidase Activities of the 20S Proteasome: Among the 14 different subunits (7 
and 7 ) of the 20S proteasome, only three of them exhibit active sites for peptide bond hydrolysis,
namely 1 (caspase-like), 2 (trypsin-like) and 5 (chymotrypsin-like). The chymotrypsin-like
activity cleaves after amino acids with large or hydrophobic side chains, the trypsin-like activity
cleaves after basic residues, and the caspase-like activity is a post-glutamyl activity that cleaves
after acidic amino acids [142]. The 5-associated chymotrypsin-like activity seems to be the initial
and rate-limiting step in protein degradation by the 20S proteasome [90]. The 20S proteasome is
a threonine protease in which the nucleophilic attack is mediated by the N-terminal Thr [62]. The
three  subunits (1, 2 and 5) bearing the active sites are first synthesized as precursor proteins
each containing a propeptide at the N-terminus which must be cleaved off for the subunits to
become catalytically active [165]. Processing of the three catalytically active subunits into mature
forms occurs only after their incorporation into 20S proteasomes.
Proteasome Activation: One of the major challenges that we are faced with is to figure out how
to single out the UPP as a therapeutic target for preventing neurodegeneration. The challenge rests
7

on developing therapeutic strategies that will enhance degradation of oxidatively-modified and
toxic proteins generated by a lifetime’s worth of environmental damage, without compromising
the normal function of the UPP. One of the most appealing targets is the proteasome, the biogenesis
of which is a highly organized multistep event. It appears that in eukaryotes the cellular level of
active proteasomes is regulated at the level of assembly.
(1) Genetic Activation of the Proteasome: The stable overexpression of the β5 subunit in
primary human fibroblasts results in elevated levels of other β subunits, and increases the levels of
all three proteasome activities [19]. This genetic manipulation results in increased survival against
oxidants and a delay in senescence. The same group in a follow up study achieved proteasomal
up-regulation via overexpression of the POMP protein, the accessory factor for proteasome
assembly in humans [18]. POMP overexpression in fibroblasts led to increased levels of assembled
and functional proteasomes, and enhanced the capacity to effectively cope with various oxidative
stressors. These data further strengthen the prospect of genetic manipulation of the proteasomal
system.
(2) Proteasome activation by natural or synthetic compounds: SDS and some fatty
acids were shown to stimulate proteasome activity in vitro by favoring the open conformation of
the proteasome [26]. In addition, some proteasome-activating hydrophobic peptides bind as
modifiers at non-catalytic sites, thus mimicking the effect of the 11S complex by opening the gate
of the α-rings [91]. Katsiki et al., isolated oleuropein, the most abundant phenolic compound in
Olea europaea leaf extract, olive oil, and olives, and demonstrated that it has a stimulatory impact
on proteasome activity in vitro, probably acting through conformational changes of the gate of 20S
α-ring [89]. Some natural antioxidants such as dithiolethione and sulforaphane, were also shown
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to enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway,
resulting in increased protection against various oxidants [99,99].
1.3.

IU1 – A SMALL MOLECULE INHIBITOR OF Usp14

Accumulation

and

aggregation

of

misfolded proteins is a common feature
of many neurodegenerative diseases
[138]. Increased levels of ubiquitinated
and
Figure 3. Usp14 inhibitor, IU1

oxidized

proteins

including

ubiquitinated Tau found in brains of AD

patients point to impairment of the ubiquitin proteasome pathway (UPP) [62]. The UPP is essential
for maintaining cellular homeostasis as it ensures degradation of dysfunctional proteins and
regulates many physiological processes.

However, its efficacy declines with age and in

neurodegeneration, therefore any means that preserve proteasome activity will serve as a strategy
to delay/prevent the onset of neuropathological symptoms. Recent findings show that it can be
achieved by inhibiting the deubiquitinating enzyme Usp14 with a small molecule IU1 [101].
Mammalian proteasomes are associated with three DUBs: Rpn11, Uch37 and Usp14.
Rpn11 is a stoichiometric subunit of the proteasome unlike Uch37 and Usp14 which are only
reversibly associated with it [48]. Rpn11-dependent deubiquitination is linked to translocation and
degradation as the substrate will be deubiquitinated only after it has committed to degradation
[193]. Such commitment step is absent in Uch37 and Usp14-dependent mode of action [65,100].
Both of them shorten the ubiquitin chain from the distal tip prior to substrate degradation rather
than en bloc as is the case with Rpn11. Apparently, tagged substrates can dissociate from the
proteasome and thus escape degradation if the rate of chain trimming is faster than the rate leading
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to protein degradation. This can contribute to accumulation of dysfunctional proteins. Usp14 slows
down degradation of several proteasome substrates, such as Tau, cyclin B, and TDP-43 [104]. Its
catalytic mutant shows much less inhibition implicating that it is the chain trimming action that
slows down substrate degradation. These observations led to the screening of small molecules that
would be capable of inhibiting the catalytic activity of Usp14. 1-[1-(4-Fluoro-phenyl)-2,5dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone, known as IU1, seems to specifically inhibit
Usp14 when screened against a panel of DUBs [104]. IU1 inhibits ubiquitin chain trimming
concomitant with increased degradation of several proteins. The effect of IU1 was tested in vitro
and in vivo in murine embryonic fibroblasts (MEFs) and the HEK293 cell line on a number of
proteasome substrates including Tau. The results suggest that IU1, a small molecule inhibitor of
Usp14, enhances the degradation of proteasomal substrates. Subsequent experiments on usp14-/MEF cell cultures confirmed that increased degradation rates were due to inhibiting Usp14 with
IU1 since treatment of usp14-/- MEF with IU1 stabilized Tau and TDP-43 as well as levels of
ubiquinated proteins rather than cause more efficient degradation. IU1 also proved to be effective
in increasing clearance of oxidized proteins induced by menadione or H2O2 treatment[104].
Overall these studies strongly support that IU1 effectively enhances proteasome-dependent
degradation, a feature that can be applied to eliminating toxic proteins. However, if IU1 is to be
used in a clinical setting, its effects need to be assessed in neurons to establish its potential as a
new therapeutic approach to intervene in the neurodegeneration process.
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1.4.

INTERPLAY

BETWEEN

UPP

AND

MITOCHONDRIA:

ITS

ROLE

IN

NEURODEGENERATION
Cellular homeostasis and viability strongly depend on optimal mitochondrial and ubiquitin-

proteasome

pathway

(UPP)

function. Impairment of the UPP,
mitochondrial

activity

and

oxidative stress are implicated in
aging

and

neurodegenerative

diseases. Recent studies showed
that interfering with the UPP or
mitochondria

results

in

pathological conditions and can
Figure 4. Interplay between UPP and mitochondria

lead to cell death. The UPP
depends on mitochondria for ATP production which is needed for (a) ubiquitin activation by the
E1 enzyme, the first step of the ubiquitination cascade, and (b) proteasome-mediated protein
degradation as substrate unfolding and translocation into the degradation chamber, as well as
assembly of the 26S proteasome are energy-dependent processes [112]. Mitochondrial integrity,
on the other hand depends on UPP-mediated protein quality control. Among the many proteins
targeted for degradation by the proteasome are aberrant mitochondria-destined proteins and
proteins involved in maintaining balance between mitochondrial fusion and fission, like Fzo1, a
protein involved in mitochondrial fusion or Fis1 and Drp1, essential components of mitochondrial
fission machinery [119]. Numerous studies demonstrated that proteasome inhibition results in
accumulation of ubiquinated mitochondrial proteins and impaired mitochondrial dynamics like
increased/decreased fragmentation, aggregation or mitochondrial swelling which is detrimental to
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the cell . UPP is also involved in the turnover of mitochondria by means of the E3 ubiquitin ligase
- Parkin, which is recruited to damaged mitochondria to mediate mitophagy [136]. The link is
further confirmed by the presence of UPP components in the outer mitochondrial membrane which
participate in mitochondrial dynamics [21,133,136]. These include ubiquitin ligases MITOL and
MULAN as well as deubiquinating enzyme Ubp16/USP30 [105,134]. There is therefore, a
crosstalk between mitochondria and the UPP in a healthy neuron and its maintenance is essential
to ensure homeostasis, cellular health and viability. Accordingly, if one component of this system
sustains damage it compromises the activity of the other component and this event has a negative
impact on the entire cell and can result in apoptosis or necrosis.
The ubiquitin/proteasome pathway (UPP) plays a critical role in aging and in the
pathogenesis of AD [155] High levels of oxidized proteins detected in the aging brain as well as
in brains of AD patients are an indication of proteasome impairment, since this proteolytic complex
degrades the majority of oxidatively modified proteins [63]. Moreover, the accumulation and
aggregation of Ub-proteins detected in most neurodegenerative disorders, such as AD, is also a
sign of UPP dysfunction, since this pathway degrades Ub-proteins [79]. Dysfunctional
mitochondria contribute to oxidative stress by ROS production. Oxidative stress induced by ROS
alters the structure of cellular proteins [180] which, if not repaired, must be removed by proteolysis
to prevent their accumulation and aggregation. Impaired clearance of oxidatively modified
proteins can promote progression of the neurodegenerative process [63]. One of the major roles of
the proteasome is to degrade oxidatively modified proteins, but if the oxidative stress persists it
leads to accumulation and later aggregation of oxidized proteins which compromise proteasomal
activity. The proteasome is also susceptible to oxidation, and oxidative modification of its Rpt3
subunit results in decreased ATP-ase activity of this subunit and an overall decline in
12

ubiquitin/ATP-dependent proteolysis by the 26S proteasome [81]. This is an important issue since
there is ample evidence that neural tissue is especially vulnerable to oxidative stress, which plays
an important role in AD [38]. Neurons are especially vulnerable to ROS-induced damage due to
high O2 consumption. Brain processes 20% of basal O2 consumption of which 1-2% are converted
to ROS under physiological conditions [41]. Moreover, ROS levels are even higher when
mitochondria are damaged. Persistent oxidative stress decreases the level and activity of 26S
proteasomes with a concomitant increase in the level of 20S proteasomes. The degradation process
that is mediated by 20S proteasomes is ubiquitin/ATP-independent and may act as a cellular
strategy to conform to oxidative stress, but the mechanism that leads to the switch from 26S to 20S
is unknown. Another deleterious mechanism associated with mitochondrial dysfunction is the
limitation in ATP production that can cause an energy crisis in neurons [137]. Degradation of
proteins by the 26S proteasome is highly dependent on ATP binding and hydrolysis [112]. Both
deleterious consequences of mitochondrial impairment, i.e. restricted ATP generating capacity and
ROS production, impair proteasome-dependent proteolysis in neurons and contribute to
neurodegeneration. It is clear that there is a mutual dependence between the UPP and mitochondria
[119], but the specific mechanisms underlying the functional link between UPP and mitochondria
impairment (Fig. 4) leading to neurodegeneration in AD have not been addressed. New discoveries
in the functional links between the UPP and mitochondrial impairment and their roles in overall
neuronal homeostasis could lead to novel and successful therapeutic approaches for AD.
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1.5. ENDOGENOUS PRODUCT OF INFLAMMATION: PROSTAGLANDIN J2 (PGJ2)
Prostaglandins of the J2 series are derived
from PGD2 (Fig.5 adapted from [190]), the principle
cyclooxygenase

product

synthesized

in

the

mammalian central nervous system (CNS). PGD2
readily undergoes in vivo and in vitro non-enzymatic
dehydration to generate PGJ2, which is converted to
12-PGJ2 and 15-deoxy-12,14-PGJ2 (15d-PGJ2)
[183]. Unlike most other classes of prostaglandins,
Figure 5. Conversion of PGD2 to PGJ2

cyclopentenone

PGs

like

PGJ2

have

a

cyclopentenone ring with reactive ,-unsaturated carbonyl groups (red asterisks, left scheme).
These highly reactive carbonyl groups form covalent Michael adducts with nucleophiles such as
free sulfhydryls in cysteine residues of glutathione and cellular proteins [183]. In neuronal cells
prostaglandins of the J2 series induce apoptosis [43,57,129], inhibit mitochondrial activity
[95,122,181] as well as 26S proteasome activity [198], and trigger accumulation and aggregation
of ubiquitinated proteins [107]. The chemical properties of prostaglandins of the J2 series and their
pro-oxidant and UPP disrupting effects render them extremely neurotoxic and capable of inducing
neuronal cell death [190].
Our studies focus on PGJ2 because it is an endogenous product of inflammation that causes
pleiotropic changes that mimic many of the pathological processes that occur in neurodegenerative
disorders that are associated with inflammation, such as AD and Parkinson’s disease (PD). It has
been suggested that “formation of cyclopentenone eicosanoids [such as PGJ2] in the brain may
represent a novel pathogenic mechanism that contributes to many neurodegenerative conditions”
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[131]. Moreover, PGJ2 up-regulates the expression and activity of cyclooxygenase-2 (COX-2), a
prostaglandin synthesizing enzyme. PGJ2 thus has potential to initiate a series of deleterious
cascades leading to self-sustained progressive neurodegeneration. Cyclooxygenases are key
players in inflammation and they mediate the conversion of arachidonic acid into an assortment of
products. Arachidonic signaling through the cyclooxygenase pathway yields an enormous variety
of products, some of them with pro-survival, others with pro-death effects. For instance,
prostaglandins are known to be pro-inflammatory under certain conditions and anti-inflammatory
under others [reviewed in [201]]. The dual role of prostaglandins is quite complex as a single
prostaglandin can bind to multiple receptors. For example, two receptors (DP1 and DP2) were
identified for PGD2 the most abundant prostaglandin in the CNS. DP1 activation increases cAMP,
activates protein kinase A and is linked to an anti-inflammatory response, while DP2 activation
increases the cellular influx of calcium and triggers a pro-inflammatory response [reviewed in
[163]]. PGD2-mediated activation of DP1 was found to be neuroprotective while DP2 activation
was neurotoxic [109]. Besides binding to different receptors some prostaglandins, such as PGD2,
are spontaneously metabolized by non-enzymatic dehydration to cyclopentenone prostaglandins,
such as PGJ2. Cyclopentenone prostaglandins may have an anti-inflammatory effect by inhibiting
the NFB pathway or a neurotoxic effect by inducing apoptosis [reviewed in [131]]. In our
laboratory we use PGJ2 to induce pathological events relevant to AD in in vitro as well as in vivo
studies. PGJ2 causes proteasome impairment, increases the levels of ubiquinated proteins, caspase3 activation, caspase-3-dependent Tau cleavage at Asp421 that leads to formation of aggregationprone ∆Tau, and formation of ubiquitin aggregates in rat E18 cerebral cortical neurons. PGJ2 also
induces loss of dopaminergic neurons in SNpc when injected into mouse brain in a PD mouse
model [176].
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1.6. NEUROPROTECTION BY PACAP27-INDUCED cAMP SIGNALLING PATHWAY
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the
VIP/secretin/glucagon/ hormone superfamily that was first isolated from ovine hypothalamic
extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells [125].
PACAP is widely distributed throughout the body [191] and has been shown to regulate important
biological functions, like control of neurotransmitter release, vasodilation, activation of intestinal
motility, increase in insulin and histamine secretion, stimulation of cell proliferation [191].
PACAP is also expressed in the CNS and is known to exhibit neurotrophic and neuroprotective
properties [2,13]. PACAP exists in two forms: one contains 38 amino acids (PACAP38), and the
other one 27 amino acids (PACAP27).
The action of PACAP is exerted by specific binding to PAC1 as well as to VPAC1 and
VPAC2 G proteins coupled receptors. Binding to VPAC receptors is less specific as vasoactive
intestinal peptide (VIP) also binds to them with affinity similar to that of PACAP. PAC1 receptors
are mainly distributed in the CNS, pituitary and adrenal glands while VPAC receptors are found
mainly in lungs, liver and urogenital tract [67,175]. PAC1 receptor is a G-protein coupled receptor
which increases intracellular cAMP levels through adenylate cyclase and activates PKA. It can
also induce MAP kinase cascades. PACAP and PAC1R expression were mapped to hippocampus,
cerebral cortex, basal ganglia, and other brain areas affected in neurodegenerative diseases.
Numerous studies showed that PACAP promotes cell survival in various models of
neurodegenerative diseases [152,153,187]. For example, in in vitro PD models of
neurodegeneration induced by incubating cultures with 6-hydroxydopamine [186], MPTP [186]
or rotenone [196], PACAP enhanced dopamine uptake, increased the number of TH-reactive
neurons and prevented apoptotic cell death in a dose dependent manner. In in vivo models of PD
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induced by 6-OHDA [153] or MPTP [195], PACAP27 treatment rescued neurons in the substantia
nigra pars compacta. It also increased expression of D2 receptors in striatum and improved
behavioral deficits. Other beneficial effects against brain damage include neuroprotection in
middle cerebral artery occlusion (MCAO) by reducing the infarct volume as well as in traumatic
brain injury (TBI) [17]. PACAP levels were shown to be downregulated along with other
neurotrophic factors in mouse models of AD which may in part account for increased death of
neurons [200]. In vitro studies with AD models using Aβ showed that PACAP protects neurons
against the toxic effects of Aβ by reducing caspase-3 activity and thus apoptosis [141]. PACAP
also preserved mitochondrial activity and increased alpha-secretase activity. PACAP exerts its
neuroprotective effect through multiple pathways. It is strongly anti-apoptotic and antiinflammatory [31]. It also acts on astrocytes and has anti-oxidant effects. Neurodegenerative
diseases, like AD, are characterized by proteasome impairment which strongly contributes to
neuropathological symptoms. Therefore means to increase proteasome activity would be useful as
potential therapeutic approaches. PACAP provides for such approach, through activation of the
cAMP-signaling pathway. Elevating cAMP levels has neuroprotective properties via preventing
caspase-3 activation in an in vitro model of AD [124] but also exerts positive effects on the UPP
pathway. cAMP activates PKA which in turn phosphorylates Rpt6, a subunit of the 19S regulatory
particles that contributes to 26S proteasome stability [35]. cAMP/PKA signaling thus increases
26S proteasome activity and also elevates the expression of proteasome subunits RPt6 and to a
lesser extent β5. Our previous in vitro studies demonstrated that increasing intracellular levels of
cAMP via PACAP27 prevented caspase-3-dependent Tau cleavage at Asp421 leading to ∆TAU
[124] formation induced by PGJ2, as well as protein aggregation induced by PGJ2. Overall, current
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in vitro and in vivo data support the notion that elevating cAMP via PACAP27 prevents AD-like
neuropathological symptoms such as PGJ2-induced TAU aggregation and caspase-3 activation.
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2.1. ABSTRACT
Proteasome activity is reportedly downregulated in Alzheimer’s and Parkinson’s diseases,
thus increasing proteasome activity could be therapeutically beneficial. The proteasome-associated
deubiquitinase Usp14 disassembles polyubiquitin chains, potentially delaying proteasomedependent protein degradation. We assessed the protective efficacy of inhibiting or
downregulating Usp14 in rat and mouse (Usp14axJ) neuronal cultures treated with prostaglandin
J2 (PGJ2). The product of inflammation PGJ2 is neurotoxic and induces accumulation and
aggregation of ubiquitinated (Ub)-proteins. We established that: inhibiting Usp14 with high IU1
concentrations (HIU1, >25 µM) reduces the accumulation of Ub-proteins induced by PGJ2, while
low IU1 concentrations (LIU1, ≤25 µM) have no impact; HIU1 alone or with PGJ2 is neurotoxic,
and induces calpain-dependent cleavage of Tau, caspase and spectrin; HIU1 decreases E1~Ub
thioester formation and 26S proteasome assembly, which are energy-dependent processes. We
attribute the two latter HIU1 effects to ATP-deficits and mitochondrial Complex I inhibition, as
shown herein. These HIU1 effects mimic those of mitochondrial inhibitors, such as oligomycin.
Thus, we propose that ATP-depletion is a major mediator of HIU1-actions. Moreover, Usp14
knockdown by siRNA in rat cultures or loss of Usp14 exhibited in cultures from ataxia (Usp14axJ)
mice, failed to prevent Ub-protein accumulation induced by PGJ2-treatment. We also show that
PGJ2 alone induces Ub-protein accumulation and decreases E1~Ub thioester formation. This
seemingly paradoxical result may be explained by PGJ2 inhibiting deubiquitinases resulting in
Ub-protein stabilization. In conclusion, we demonstrate that the decline in Ub-protein levels
induced by IU1 in neurons correlates with decreased E1~Ub thioester formation rather than with
proteasome enhancement.
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2.2. INTRODUCTION
The ubiquitin/proteasome pathway (UPP) and autophagy play a critical role in protein
quality control and thus have attracted special attention for drug development [39]. Alzheimer’s
(AD) and Parkinson’s (PD) diseases are of particular interest since a hallmark of these
neurodegenerative disorders is accumulation/aggregation of Ub-proteins in specific areas of the
CNS [157]. A potential therapeutic strategy for these disorders could be directed towards
deubiquitinases to prevent the accumulation and aggregation of Ub-proteins [24].
In humans there are around one hundred genes encoding deubiquitinases from five
different families, four of them being thiol proteases and one a metalloprotease [40].
Deubiquitinases perform a range of functions, including processing newly translated ubiquitin
(Ub) to provide monomers for conjugation and chain formation, trimming mono-Ub from the distal
end of a poly-Ub chain, disassembling poly-Ub chains, and removing poly-Ub chains from
substrates [20]. Overall, these functions provide a means for deubiquitinases to regulate “where,
when and why” ubiquitinated substrates are degraded by the 26S proteasome [157].
The deubiquitinase Usp14 is important for development and functioning of the nervous
system [23]. Homozygous Usp14 null mice (ataxia mice) exhibit developmental abnormalities
including motor impairment, reduced brain mass and death by 2 months of age [25]. Usp14
associates transiently with the proteasome and exhibits Ub-chain trimming activity, thereby
replenishing the Ub pool [11]. This deubiquitinase can cause premature dissociation of substrates
from the proteasome, if ubiquitin removal is faster than the competing steps leading to substrate
degradation [11]. Inhibiting or downregulating Usp14 was proposed as a therapeutic approach for
promoting the efficient proteasomal elimination of Ub-proteins by preventing premature trimming
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of their Ub-chains [101].
Selective and reversible inhibition of Usp14 can be achieved with 1-[1-(4-Fluoro-phenyl)2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone, a small molecule known as IU1 [101].
Treatment of murine embryonic fibroblasts (MEFs) and human embryonic kidney (HEK)293 cells
with IU1 resulted in the apparent increased degradation of the proteasome substrates Tau, TDP-43
and ataxin-3, which have been implicated in neurodegenerative diseases [101]. These studies
suggest that IU1 or IU1-like drugs could be used therapeutically to prevent the neurotoxic buildup of such proteins.
To test if IU1 prevents accumulation of neuronal Ub-proteins, we treated rat and mouse
cerebral cortical neurons with the endogenous product of inflammation prostaglandin J2 (PGJ2)
[47]. PGJ2 is a product of spontaneous dehydration of prostaglandin D2 (PGD2). The latter is the
most abundant prostaglandin in the brain [71,172,190] and the one that increases the most under
pathological conditions [109]. In rodents, the in vivo concentration of free PGJ2 in the brain upon
stroke and traumatic brain injury increases from almost undetectable to the 100 nM range
[115,116]. These values represent average brain levels. Regional brain concentrations of PGJ2 are
potentially higher [117], as PGJ2 binds covalently to proteins, and therefore, free PGJ2 does not
represent its total amount. Unlike most prostaglandins, PGJ2 and its metabolites have a
cyclopentenone ring with reactive ,-unsaturated carbonyl groups. These carbonyl groups form
covalent Michael adducts with cysteine thiols of glutathione or cellular proteins [183].
Electrophiles, such as PGJ2, that bind to specific protein cysteine(s) are regarded to play an
important role in determining neuronal survival [162].
We previously established that PGJ2 is the most toxic of four prostaglandins that we tested
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in neuronal cells, including PGA1, D2, E2 and J2 [108]. In addition, PGJ2 impairs the UPP by
targeting different components of this pathway including the 26S proteasome by perturbing its
assembly [139,198], deubiquitinases such as UCH-L1 and Ub isopeptidase activities
[93,108,115,130], and by causing the accumulation/aggregation of Ub-proteins [108,116]. Besides
its effects on the UPP, we showed that PGJ2 activates caspases and caspase-mediated proteolysis
in primary cerebral cortical neuronal cultures, leading to Tau cleavage and pathology [3,124]. In
sum, PGJ2 induces a range of pathological processes relevant to neurodegenerative disorders [47].
In the current study we demonstrate that inhibition of Usp14 with high concentrations of
IU1 (HIU1, >25 µM) prevents/reduces the accumulation of Ub-proteins in rat cerebral cortical
neuronal cultures treated with PGJ2. This effect of HIU1 can be attributed in part to a decline in
E1-dependent ubiquitin activation, as we show that IU1 lowers E1~Ub thioester levels. The latter
is consistent with the observed drop in ATP levels and mitochondrial Complex I activity induced
by HIU1. HIU1 was also neurotoxic and induced calpain-dependent cleavage of Tau, spectrin and
caspase. Overall, the effects of HIU1 on neuronal Ub-protein levels, E1- and calpain-activities, Tau
cleavage and ATP levels, mimic those of mitochondrial inhibitors, such as oligomycin [78]. Lower
IU1 concentrations (LIU1, 25 µM), or downregulating Usp14 by siRNA, or loss of Usp14
(Usp14axJ mouse) had no impact on Ub-protein levels. We also established that PGJ2 lowers
E1~Ub thioester levels without directly inhibiting E1 activity. In contrast to IU1, PGJ2 promotes
the accumulation of Ub-proteins in neuronal cultures. In conclusion, a deeper understanding of the
mechanisms that regulate Ub-protein accumulation, including the balance among E1,
deubiquitinase and proteasome activities, is critical for drug development that aims at reducing the
accumulation of aberrant proteins in the CNS of patients with chronic neurodegenerative diseases.
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2.3. MATERIALS AND METHODS
2.3.1. Materials: Chemicals: IU1 (Life Sensors, Malvern, PA); calpeptin (Calbiochem/EMD
Bioscience, Gibbstown, NJ); proteasome substrate Suc-LLVY-AMC (BACHEM Bioscience Inc.,
King of Prussia, PA); PGJ2 (Cayman Chemical, Ann Arbor, MI); oxidative phosphorylation
substrates, creatine phosphokinase, and bovine ubiquitin (Sigma-Aldrich, St. Louis, MO). Primary
antibodies: chicken polyclonal anti-Usp14 (1:1,000, cat# AB505) from Life Sensors, Malvern PA;
rabbit polyclonal anti-ubiquitinated proteins (1:1,500, cat# Z0458) from Dako North America,
Carpinteria, CA; rabbit polyclonal anti-β5 (1:5,000, cat# PW8895), and mouse monoclonal antiRpt6 (1:2,000, cat# PW9265), from ENZO Life Sciences, Inc., Farmingdale, NY; mouse
monoclonal anti-β-actin (1:10,000, cat# A-2228) from Sigma, St. Louis, MO; mouse monoclonal
anti-spectrin α chain (clone AA6, cat# MAB1622) from Millipore, Billerica, MA; mouse
monoclonal Tau C3 (1:5,000; detects Tau cleaved at Asp421; ep: a.a. 412–421) and mouse
monoclonal Tau C5 (1:50,000; detects all Tau isoforms and ΔTau; ep: a.a. 210–241) were courtesy
of Dr. L. Binder (Northwestern University, Chicago, IL, USA); rabbit polyclonal anti-UBE1a
(1:1000, cat# 4890) and anti-caspase 3 (1:1000, cat# 9662) from Cell Signaling Technology,
Danvers, MA. Secondary antibodies with HRP conjugate (1:10,000) from Bio-Rad Laboratories,
Hercules, CA.
2.3.2. Mice - C57BL/6J mice (wild type) and Usp14axJ mice maintained on a C57BL/6J
background (Jackson Laboratories, Bar Harbor, MA) have been maintained in the breeding colony
at the University of Alabama at Birmingham. Homozygous Usp14axJ mice were generated by
intercrossing heterozygous axJ siblings.
2.3.3. Cell cultures - Dissociated cultures from Sprague Dawley rat embryonic (E18, both sexes)
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cerebral cortical neurons were prepared as in [78]. Dissociated cultures from wild type and
homozygous Usp14axJ mouse embryos were prepared as in [28]. The isolated cortices free of
meninges were digested with papain (0.5 mg/ml from Worthington Biochemical Corp.) in
Hibernate E without calcium (BrainBits LLC.) at 37oC for 30 min in a humidified atmosphere
containing 5% CO2. After removal of the enzymatic solution, the tissues were gently dissociated
in Neurobasal media (Invitrogen). Dissociated tissues were centrifuged at 300Xg for 2 min. The
pellet was resuspended in Neurobasal media without antibiotics and plated on 10 cm dishes precoated with 50 µg/mL poly-D-lysine (Sigma). Cells were plated at a density of 6X106 cells per 10
cm dish, or 2.5X105 cells per well on 24-well plates (cell viability only). Cultures were maintained
in Neurobasal media supplemented with 2% B27 and 0.5 mM L-Glutamax (all from Invitrogen)
at 37°C in a humidified atmosphere containing 5% CO2. Half of the medium was changed every 4
days. Experiments were run 8-11 DIV. According to manufacturer’s specifications, Neurobasal
medium contains several proprietary factors that ensure a mostly pure (> 95%) neuronal culture;
glial growth is inhibited without a need for the anti-mitotic agent arabinofuranosyl cytidine
[14,135].
2.3.4. Culture treatments – Cortical neurons were treated acutely (4 h, 8 h, 16 h or 24 h) with
DMSO or with the different drugs in DMSO added directly to DMEM without serum,
supplemented with 0.5 mM L-Glutamax and 1 mM sodium pyruvate (all from Invitrogen). The
final DMSO concentration in the medium was 0.5%.
2.3.5. Cell viability assay - Cell viability was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) assay as described [128].
2.3.6. ATP assay - Steady state ATP content was measured with a kit using the sensitive
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luciferin/luciferase system (Molecular Probes). This assay is based on luciferase requiring ATP
for light production using luciferin as a substrate. Cells were harvested with 4% trichloroacetic
acid followed by centrifugation (19,000Xg, 15 min at 4ºC). ATP steady state levels were
determined in cleared supernatants after neutralizing the samples with 1 M Tris-HCl, pH 8.0.
Samples were then added to the reaction buffer containing luciferin and assayed using a
Luminoskan Ascent microplate luminometer (Thermo Electron Corporation). Protein
concentration was determined with the bicinchoninic acid (BCA) assay kit (Pierce) after
resuspending the pellet in10 mM Tris-HCl (pH 8.0) and 1% SDS followed by sonication. ATP
levels were normalized to protein concentration determined with the BCA assay.
2.3.7. Mitochondrial respiratory chain complex activities - Bovine heart submitochondrial
particles (SMP) were prepared according to standard procedures [53] and stored in liquid nitrogen.
Before activity measurements, SMP were resuspended to 5 mg/ml in SET buffer pH 7.5 (0.25 M
sucrose, 0.2 mM EDTA, 50 mM Tris-HCl), containing 0.2 mM malonate and incubated at 30°C
for
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min.

NADH-dependent

enzymatic

activities

of

Complex

I

were

assayed

spectrophotometrically (Perkin Elmer Lambda 35) as a decrease in absorption at 340 nm (ε340 nm
= 6.22 mM-1 cm-1) with 150 μM NADH in SET buffer containing 2.5–25 μg of protein/ml SMP.
For the measurements of NADH:Q1 or NADH:HAR oxidoreductase activity, SMP were assayed
in the presence of 1 mM cyanide with the addition of 80 μM Q1 or 1 mM HAR, respectively. The
Complex IV activity was measured at 550 nm (ε550nm = 21.5 mM-1 cm-1) with 45 µM
ferrocytochrome c in two fold diluted SET buffer containing 0.025% laurilmaltoside and 2.5-5 μg
of protein/ml SMP. Since IU1 strongly absorbs in the near UV region, succinate oxidase activity
was measured as oxygen consumption using Oroboros oxygraph in SET buffer containing 5 mM
succinate and 20 μg of protein/ml SMP. To measure the effect of IU1 on respiratory chain
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enzymes, SMP were preincubated directly in the measuring medium for 2 min with the inhibitor
before initiating the reaction with a substrate. Separate control studies confirmed the preincubation
time was sufficient to reach equilibrium in the enzyme-inhibitor reaction. All activities were
measured at 30°C and expressed in µmol of substratemin-1mg-1. Protein concentration was
determined with the BCA assay. Reported values are the mean ± SD (at least 3 independent
experiments).
2.3.8. Western blotting - After treatment, cells were rinsed twice with PBS and harvested by
gently scraping into ice-cold lysis buffer [20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1 mM EGTA,
2.5 mM Na4P2O7, 1 mM β-glycerophosphate, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride,
1% NP40, 1 mM Na3VO4, 1% Glycerol and protease inhibitor cocktail (Sigma-Aldrich, St Louis,
MO)]. Following lysis (at least 30 min, -80oC), cell extracts were centrifuged (19,000xg for 10
min) at 4oC. Protein concentration of the NP40-soluble supernatants was determined with the BCA
assay. Western blot analysis was carried out following SDS-PAGE. Normalized samples were
boiled for 5 min in Laemmli buffer and loaded onto gels (30 µg of protein/lane). Following
electrophoresis, proteins were transferred onto an Immobilon-P membrane (Millipore, Bedford,
MA, USA). The membrane was probed with the respective antibodies, and antigens were
visualized by a standard chemiluminescent horseradish peroxidase method with the ECL reagent.
Semi-quantitative analysis of protein detection was done by densitometry including image analysis
with the ImageJ program (Rasband, W.S., ImageJ, U.S. NIH, Maryland, http://rsb.info.nih.gov/ij/,
1997-2006).
2.3.9. Evaluation of endogenous E1~ubiquitin thioester – Upon treatment with vehicle (control,
DMSO) or with the respective drugs, cortical neurons were washed once with PBS, harvested with
a thiol stabilizing buffer [5 mM Tris-HCl, pH 7.8, 8.7 M urea, 1% Nonidet P-40, 20 mM N27

ethylmaleimide, 3 mM EDTA, 2% protease inhibitor cocktail (Sigma)], and kept on ice for 15 min
for lysing, as described [85]. Samples were sonicated for 10 s, centrifuged at 19,000Xg for 15 min
at 4oC, mixed (30 μg) 1:2 (volume) with thioester gel buffer (33 mM Tris-HCl, pH 6.8, 2.7 M urea,
2.5% SDS and 13% glycerol), and boiled for 5 min. After determination of the protein
concentration with the Bradford assay (Bio-Rad Laboratories), the normalized samples were
separated into reducing (with 4% -mercaptoethanol) and non-reducing (no -mercaptoethanol)
aliquots for SDS-PAGE, followed by western blotting with anti-E1 antibody, as described above.
2.3.10. In vitro E1 activity assay– Commercial bovine ubiquitin was further purified to apparent
homogeneity by FPLC and quantified spectrophotometrically [5]. Ubiquitin was radioiodinated
by the Chloramine-T procedure using carrier-free Na125I to yield a specific radioactivity of
∼20,000 cpm/pmol [64]. Human Uba1 was purified to apparent homogeneity from outdated
erythrocytes and active Uba1 was determined by the stoichiometric formation of

125

I-ubiquitin

thioester [64]. One pmol of Uba1 was pre-incubated with 0.5% DMSO (vehicle) or 15 μM PGJ2
(0.5% DMSO) at 4°C in 50 mM Tris-HCl (pH 7.5) for 0, 1, 2, 4, 6, 12, and 24 hours. Formation
of E1 thioester was analyzed at 37°C in 25 μl reactions containing 50 mM Tris-HCl (pH7.5), 1
mM ATP, 10 mM MgCl2, 10 mM creatine phosphate, 1 IU of creatine phosphokinase and an
aliquot of the time point equivalent to 40 nM Uba1 (original content). Reactions were started by
the addition of 4 μM

125

I-ubiquitin and quenched after 1 min by the addition of 25 μl 2X SDS

sample buffer. The E1~125I-ubiquitin thioesters were resolved from free

125

I-ubiquitin by 12%

SDS-PAGE under non-reducing conditions at 4°C and visualized by autoradiography. Where
indicated, E1 was quantified by excising the E1~125I-ubiquitin thioester band, quantifying
associated radioactivity by gamma counting, and calculating absolute thioester formation using
the corrected specific radioactivity of the 125I-ubiquitin [64].
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2.3.11. In gel proteasome activity and levels – Upon treatment with vehicle (control, DMSO) or
the respective drugs, cells were washed twice with PBS and harvested for the in gel assay as
described in [132]. The native gels loaded with 30 µg protein/lane, were run at 150 V for 120 min.
The in gel proteasome activity was detected by incubating the native gel on a rocker for 10 min at
37oC with 15 ml of 300 μM Suc-LLVY-AMC followed by exposure to UV light (360 nm). Gels
were photographed with a NIKON Cool Pix 8700 camera with a 3-4219 fluorescent green filter
(Peca Products, Inc). Proteins on the native gels were transferred (110 mA) for 2 h onto PVDF
membranes. Immunoblotting was carried-out for detection of the 20S and 26S proteasomes with
the anti-Rpt6 and anti-β5 antibodies, which react with subunits of the 19S or the 20S particles,
respectively. Antigens were visualized by a chemiluminescent horseradish peroxidase method
with the ECL reagent.
2.3.12. Caspase-3 and calpain activation - Cell lysates were analyzed by standard western
blotting with the anti-caspase-3 antibody to detect caspase-3 cleavage that is indicative of
apoptosis. Calpain activation was assessed with the anti-α-spectrin antibody. Calpain cleavage of
α-spectrin generates a 150/145 kDa doublet, while caspase cleavage generates a 120 kDa fragment
[197].
2.3.13. siRNA – The dicer siRNA substrates targeting the Usp14 gene obtained from IDT
(Coralville, Iowa), were encapsulated into lipid nanoparticles using microfluidic technology by
Precision NanoSystems (SUB9KITSTM; Vancouver, Canada). Cells were treated with 0.1 µg/ml
of Neuro9TM RNAi nanoparticles as described in [161] for 72 h prior to treatment with 10 µM
PGJ2 for 16 h. During siRNA treatment, cells remained in Neurobasal media supplemented with
2% B27 and 0.5 mM L-Glutamax (all from Invitrogen) at 37°C in a humidified atmosphere
containing 5% CO2. Following the 72 h incubation period with siRNA, the medium was changed
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to DMEM without serum, supplemented with 0.5 mM L-Glutamax and 1 mM sodium pyruvate
(all from Invitrogen) and cells were treated with 10 µM PGJ2 for 16h.
2.3.14. Statistical analysis - Statistical significance was estimated using one-way ANOVA
(Tukey-Kramer multiple comparison test) or the Welch's t-test (two group comparison) with the
Prism 6 program (GraphPad Software, San Diego, CA).
2.4. RESULTS
2.4.1. IU1 blocks PGJ2-induced accumulation of ubiquitinated proteins and triggers calpainmediated cleavage of Tau, caspase 3 and spectrin – Since IU1 was proposed to promote protein
degradation by the proteasome [101] we examined its effects on neuronal Ub-protein levels. IU1
was not previously tested on neurons [101]. To increase the endogenous levels of Ub-proteins, the
rat cerebral cortical neuronal cultures were treated with the product of inflammation PGJ2
[174,190]. The neurons were pre-incubated with IU1 (75 µM) for 6 h prior to PGJ2 treatment (15
µM, 16 h). A similar protocol was used to establish protection by IU1 against proteotoxic stress in
HEK293 cells treated with menadione, an oxidative stressor [101]. As expected, PGJ2 significantly
increased the levels of Ub-proteins but IU1 by itself did not (Fig. 6, lanes 2 and 3, panels 1 and
2). In addition, IU1 blocked the accumulation of Ub-proteins induced by PGJ2 (Fig. 6, compare
lanes 2 and 4, panels 1 and 2). Compared to control conditions (lane 1) the levels of free Ub were
not decreased by any of the treatments (Fig. 6, panels 1 and 2).
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Figure 6. IU1 blocks PGJ2-induced
accumulation

of

proteins

triggers

and

ubiquitinated
calpain-

mediated cleavage of Tau, caspase 3
and spectrin
NP-40 soluble fractions from rat E18
cerebral cortical neurons treated as
indicated were analyzed by western
blotting (30 μg of protein/lane) and
probed with the respective antibodies
to assess the effect of the treatments
on: level of ubiquitinated proteins
(panel 1 and 2), Tau FL (full-length)
and other Tau fragments (panel 3), Tau
cleaved at Asp412, Tau (panel 4),
caspase 3 (panel 5), α-spectrin (panel
6),

actin as loading control (panel 7).

Molecular mass markers in kDa are
shown on the left.

IU1 was previously shown to promote the degradation of a Tau isoform overexpressed in
wild type MEFs [101]. Tau is a microtubule associated protein that is abundant in neurons and
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highly soluble, yet Tau forms abnormal aggregates and is the major component of neurofibrillary
tangles, one of the hallmarks in AD [121]. Confirming what we previously demonstrated [124],
PGJ2 induced caspase-mediated cleavage of Tau (Tau, Fig. 6, panel 4, lane 2). Tau is prone to
aggregation and its formation is an early event in AD tangle pathology [29,54,156]. In contrast to
PGJ2, IU1 induced calpain-mediated cleavage of Tau (Fig. 6, panel 3, lane 3), reminiscent of what
we observed in cortical neurons treated with the mitochondrial inhibitor oligomycin [78]. IU1
combined with PGJ2 further increased calpain-mediated cleavage of Tau (Fig. 6, panel 3, lane 4).
We established that IU1-treatment induces calpain activation, while PGJ2-treatment
triggered mostly caspase 3 activation. As shown in Fig. 6 (panel 5, lane 3), IU1 triggered the
cleavage of pro-caspase 3 to a ~29 kDa inactive fragment [143] (Cl-caspase 3) and not to its active
17 kDa form (Act-caspase 3). On the other hand, PGJ2 induced the cleavage of pro-caspase 3 (33
kDa) to its active form (17 kDa, Act-caspase 3, Fig. 6, panel 5, lane 2), as we previously showed
[3]. We further confirmed that calpain was activated upon IU1-treatment by assessing cleavage of
-spectrin, a calpain substrate. IU1-treatment by itself or in combination with PGJ2 clearly
induced cleavage of -spectrin (Pro--spectrin, 280 kDa) to 145/150 kDa fragments [Cl-spectrin (150)], which are indicative of calpain activation (Fig. 6, panel 6, lanes 3 and 4). In
contrast, PGJ2-treatment mostly induced -spectrin cleavage to a 120 kDa -spectrin fragment
[Cl--spectrin (120)], which is a marker of apoptotic cell death [197]. Furthermore, pre-treatment
with the calpain inhibitor calpeptin (Z-Leu-norleucinal) prevented calpain-dependent Tau and
spectrin cleavages induced by IU1 alone (Fig. 6, panels 3 and 6, compare lanes 3 and 6). In
contrast, treatment with both calpeptin and IU1 stimulated caspase-dependent Tau cleavage the
most (Fig. 6, panel 4, lane 6), indicating caspase activation under these conditions as discussed
below.
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We next addressed if lower IU1 concentrations (25 µM) also blocked the accumulation of
Ub-proteins induced by PGJ2. For these experiments we reduced the PGJ2 concentration to 10
µM, as we also lowered IU1 levels. Adding IU1 to the neuronal cultures prior to PGJ2-treatment
had the same effect as co-incubation with the two drugs (not shown). Therefore, in all subsequent
experiments both agents were added at the same time. Although in some experiments IU1 at a 25
µM appeared to decrease the levels of Ub-conjugates induced by 4 h (Fig. 7A and 7C), or 24h
PGJ2-treatment, this effect was not statistically significant(Fig. 7B and 7C).
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Figure 7. Low concentration of IU1 (≤25 µM) did not affect the accumulation of Ub-proteins induced by
PGJ2. NP-40 soluble fractions from rat E18 cerebral cortical neurons treated as indicated were analyzed by
western blotting (30 μg of protein/lane) and probed with the respective antibodies to assess the effect of the
treatments on the level of ubiquitinated proteins (A and B) using actin as loading control. Quantification (C).
Molecular mass markers in kDa are shown. In C the levels of ubiquitinated proteins (polyUb/actin) were semiquantified by densitometry. Data represent the percentage of the pixel ratio for Ub-proteins over the respective
loading control for each condition compared to control (100%). Values are means from at least three experiments.
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2.4.2. IU1 reduces cell viability and depletes intracellular ATP levels – Calpain-activation is
linked to ATP-depletion and necrosis, a cell death pathway associated with a bioenergetic crisis
[209]. In fact, calpain-activation was shown to be induced by inhibitors of oxidative
phosphorylation, such as rotenone, antimycin and oligomycin [173]. As we established that IU1
induces calpain activation, we reasoned that IU1 may be neurotoxic and lower intracellular ATP
levels.

Figure 8. IU1 reduces neuronal viability
Neurons were treated with indicated
concentrations of IU1 and/or 10µM PGJ2.
Cell viability was assessed with the MTT
assay. Percentages represent the ratio
between the data for each condition and
control (100%). Values indicate means and
s.e.m. from at least three experiments per
group. Asterisks identify values that are
significantly different from control (*
p<0.05; ** p<0.01; *** p<0.001)

As shown in Fig. 8, IU1 caused a decline in cell viability in a concentration (panel A) and
time-dependent-manner (panel B), the latter assessed for 25 µM. In addition, treatment with PGJ2
(10 µM) and IU1 (25 µM) combined was even more neurotoxic than any of the drugs alone (panel
35

C). The loss of neuronal viability was assessed with the MTT assay, which is reduced largely
within the cytoplasm [10,118].
As we predicted, IU1 decreased ATP levels also in a concentration (Fig. 9A) and time
dependent manner (Fig. 9B). Moreover, treatment with PGJ2 (10 µM) combined with IU1 (25
µM) decreased ATP levels the most, compared to the effectiveness of either compound alone
(panel C).
The decline in ATP levels induced by the 24h treatment with 25 µM IU1 varied between
70% (Fig. 9B) and 90% (Fig. 9A) of control. The loss of cell viability under the same conditions
fluctuated between 40% (Fig. 8 A and B) and 80% (Fig. 8C) of control. This variation could reflect
somewhat the heterogeneity of the primary neuronal cultures for each experiment that are prepared
from a different set of rat embryos. The finding that neurons that exhibit a 70% to 90% loss of
ATP still exhibit low levels of viability is in line with other studies. For example, we showed that
30% of oligomycin-treated rat cortical neurons exhibiting a loss of ~78% of their ATP where still
viable [78]. In our studies, the neurons in culture are post-mitotic and not engaged in synaptic
activity or cell division thus may require low ATP levels for survival [145].
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Figure 9. IU1 depletes intraneuronal ATP
levels. Neurons were treated at indicated
time points with 25µM IU1 and/or 10µM
PGJ2. ATP steady state levels (pmoles/μg of
protein)

were

assessed

with

the

luciferin/luciferase system. Values depict
the mean and s.e.m. from at least three
determinations. Asterisks identify values
that are significantly different from control

2.4.3. IU1 inhibits mitochondrial Complex I - (These studies were carried-out by Alexander
Galkin, School of Biological Sciences, Queen's University Belfast, Belfast, BT9 7BL, United
Kingdom, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New
York, NY 10065, USA; Anna Stepanova, N.K. Koltzov Institute of Developmental Biology, Russian
Academy of Sciences, Moscow 119334, Russia). As shown in Fig. 10, NADH-oxidase (A) and
NADH:Q1 reductase (B) activities of Complex I were inhibited by IU1, the latter with an IC50 of
around 40 µM. This indicates a direct effect of IU1 on physiological oxidation of NADH by
ubiquinone in mitochondrial Complex I. At a much higher concentration IU1 also inhibited
oxidation of NADH by the artificial acceptor hexaammineruthenium (HAR, C). In addition, at this
concentration range IU1 had almost no effect on succinate-oxidase (Complex II-IV, D) or on
cytochrome c oxidase alone (Complex IV, E).
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Figure 10. IU1 inhibits mitochondrial Complex
I.

Mitochondrial

activities
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respiratory
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chain

complex

bovine

heart

submitochondrial particles (SMP) using various
concentrations of IU1 as described in ‘Materials and
Methods’ section. Reported values are the mean
±SD (at least 3 different experiments)

2.4.4. IU1-induced decline in Ub-protein accumulation correlates with E1 failure - To address
a mechanism mediating the IU1-induced decline in Ub-protein accumulation, we focused on the
E1 ubiquitin activating enzyme. E1 activity requires ATP for formation of a thioester adduct with
ubiquitin. In principle, if E1 activity is impaired, protein ubiquitination should be diminished. To
assess E1~Ub thioester levels, which are sensitive to reducing agents, the samples were run on
SDS-PAGE under reducing (with β-mercaptoethanol) and non-reducing (without βmercaptoethanol) conditions. As shown in Fig. 11A (panel 1), in the control sample under nonreducing conditions E1~Ub thioester (~126 kDa) migrated ~9 kDa above native E1 (117 kDa),
38

consistent with the additional mass of ubiquitin. PGJ2 (15 µM) or HIU1 (50 µM)-treatment
abolished the E1~Ub thioester, reflecting the loss of the ubiquitin monomer linked to E1 (Fig. 11A,
panel 1). The effect of lower IU1 concentrations (≤25 µM) alone on E1~Ub thioester was minimal.
As expected, when PGJ2 was combined with increasing concentrations of IU1 (Fig. 11A, panel
1), the E1~Ub thioester was almost undetectable.

Figure 11 A. IU1-induced decline in Ub-protein accumulation correlates with E1 failure NP-40
soluble fractions from rat E18 cerebral cortical neurons treated as indicated were analyzed by western
blotting (30 µg of protein/lane) probed with the respective antibodies to detect E1-Ub (ubiquitin) thiol
esters and native E1, run under non-reducing conditions (panel 1), or reducing conditions with βmercaptoethanol (panel 2); Ub-proteins (panel 3); actin (loading control). Quantification of total E1 levels
(from panel 2) on the right.

Under reducing conditions (Fig. 11A, panel 2) only native E1 was detected in all treatments.
PGJ2 combined with 50 µM IU1, decreased the levels of E1~Ub thioester and native E1. As shown
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on the graphs on the right, total E1 levels (E1~Ub thioester + native E1) assessed under reducing
conditions were not altered significantly (p>0.05), except in the PGJ2 plus IU1 (50 µM) treatment
(p = 0.0014, quantification shown in the graphs on the right). These data demonstrate that in
neurons HIU1-mediated ATP depletion prevents E1 from forming thioester intermediates with
ubiquitin. The latter correlates with a major down-regulation of Ub-proteins in PGJ2-treated
neurons (Fig. 11A panel 3). Unconjugated (free) ubiquitin and actin levels (Fig. 11A, panels 3 and
4, respectively) were not decreased by IU1.
2.4.5. PGJ2 induces a time-dependent decline in E1~Ub thioester formation while raising the
levels of Ub-proteins – We characterized the temporal effect of PGJ2 on E1~Ub thioester
formation and compared it with the accumulation of Ub-proteins in the rat neurons. As shown in
Fig. 11B (panel 1), 15 µM PGJ2 prevented E1~Ub thioester formation by 8 h of treatment.
Moreover, PGJ2 increased the accumulation of Ub-proteins by 8 h of incubation (Fig. 11B, panel
3), despite the absence of E1~Ub thioester formation (Fig. 11B, panel 1). This seemingly
paradoxical result is addressed below in the discussion.
To determine if the PGJ2-dependent ablation of cellular E1~Ub formation was a direct
effect, such as from covalent adduct formation at the active site cysteine of the activating enzyme,
a biochemically-defined assay for E1 thioester formation in the absence or presence of PGJ2 was
conducted (Fig. 11C). Human E1 is relatively stable in the presence of DMSO alone or in the
presence of 15 μM PGJ2 in DMSO for up to 24 hours (Fig. 11C). These studies (Fig. 11C) were
carried-out by Arthur Haas and Dustin R. Todaro, Department of Biochemistry and Molecular
Biology, LSU Health Sciences Center, New Orleans, LA 70112, USA.
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Figure 11 B, C. PGJ2 induces a time-dependent decline in E1~Ub thioester formation while raising
the levels of Ub-proteins. (B) NP-40 soluble fractions from rat E18 cerebral cortical neurons treated as
indicated were analyzed by western blotting (30 µg of protein/lane) probed with the respective antibodies
to detect E1-Ub (ubiquitin) thiol esters and native E1, run under non-reducing conditions (panel 1), or
reducing conditions with β-mercaptoethanol (panels 2); Ub-proteins (panel 3); actin (loading control). (C)
E1 thioester formation essay
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2.4.6. HIU1 induces a decline in 26S proteasomes and a concomitant increase in 20S
proteasomes –The activity and assembly/disassembly of 26S proteasomes are highly dependent
on ATP binding and hydrolysis [44,114]. We thus assessed with the native in-gel assay, the effects
of IU1 on proteasome activity and levels in the cortical neurons. The in-gel assay detects the three
assembled forms of the proteasome: 26S proteasomes with either two regulatory caps [26S(2)] or
one cap [26S(1)], and the 20S core particle alone (20S). Proteasome activity was determined with
the substrate Suc-LLVY-AMC, which assesses the chymotrypsin-like activity (Fig. 12). Under
control conditions (lanes marked with “0”), the activity of the 20S proteasome is substantially
lower than that of the 26S, because the 20S is a latent proteasome form [60]. Proteasome levels
were determined by immunoblotting with the anti-Rpt6 antibody that reacts with an ATPase
subunit of the 19S particle (Fig. 12, panel 3), and with the anti-β5 antibody (Fig. 12, panel 4). The
β5 subunit is a component of the 20S core, thus its antibody detects assembled 26S and 20S
proteasomes. It is clear that HIU1 induced a decline in 26S proteasome activity that correlates with
lower ATP levels [compare Fig 9A for ATP with Fig. 12 (panel 1) for 26S proteasome activity].
Furthermore, HIU1 blocked 26S assembly (or promoted disassembly), as its activity and levels
decreased while those of the 20S proteasome increased (Fig. 12, panels 1 and 2 for activity and
panels 3 and 4 for levels). PGJ2-mediated inhibition of the 26S proteasome is shown for
comparison. Semi-quantification of proteasome activity and levels for each condition is shown in
Fig. 12B.
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Figure 12. HIU1 induces a decline in 26S proteasomes and a concomitant increase in 20S proteasomes Neurons
were treated for 24h with 10µM PGJ2 or various concentrations of IU1 (A). Lysates (30µg/sample) were subjected to
non-denaturing gel electrophoresis as described under “Experimental Procedures”. Fully assembled 26S and 20S
proteasomal (indicated in the middle by arrows) chymotrypsin-like activity was assessed with Suc-LLVY-AMC by
the in-gel assay (panels 1 and 2). To improve detection of 20S proteasome activity, 0.04% SDS was added to the
reaction buffer in panel 2. Proteasome levels were detected by immunoblotting with anti-Rpt6 (panel 3) and anti-β5
antibodies (panel 4). Proteasome chymotrypsin-like activity and levels were quantified by densitometry (B).
Percentages represent the ratio between data for each condition and control (DMSO) considered to be 100%. Values
are means from at least three experiments. Asterisks identify values that are significantly different from control
(*p<0.05, **p<0.01, ***p<0.001).
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2.4.7. Usp14 knockdown by siRNA or Usp14 loss (Usp14axJ mouse) did not prevent the
deleterious effects of PGJ2 – To determine if lowering Usp14 levels counteracts some of the
PGJ2 effects on the neurons, we induced Usp14 knock down by siRNA prior to treatment with
vehicle (control) or PGJ2 (Fig. 13B, panel 1). Usp14 siRNA had no clear impact on the PGJ2induced changes on neuronal viability (Fig. 13A), ΔTau, the caspase-dependent Tau fragment (Fig.
13B, panel 2), activated caspase 3 (Fig. 13B, panel 3), or ubiquitinated proteins (Fig. 13B, panel
4).
Likewise, studies with cortical cultures from Usp14axJ mice which exhibit a 90-95% loss
of Usp14 (Fig 13C, panel 1), show that Usp14 depletion has no benefit against the deleterious
effects of PGJ2 tested, i.e. caspase-activation, and accumulation of Ub-proteins (Fig.13C, panels
2 to3, respectively). These studies (Fig. 13C) were carried-out by Scott M. Wilson, Department of
Neurobiology, Civitan International Research Center, University of Alabama at Birmingham,
Birmingham, AL 35294.

Figure 13 A. Usp14 siRNA had no clear impact on the PGJ2-induced changes on neuronal viability. Neurons
were treated with indicated concentrations of IU1 and/or 10µM PGJ2. Cell viability was assessed with the MTT
assay. Percentages represent the ratio between the data for each condition and control (100%). Values indicate
means and s.e.m. from at least three experiments per group. Asterisks identify values that are significantly different
from control (* p<0.05; ** p<0.01; *** p<0.001)
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Figure 13 B. Usp14 knockdown by siRNA did not prevent the deleterious effects of PGJ2 Neurons
were treated with 0.1 µg/ml of Neuro9TM RNAi nanoparticles targeting Usp14 gene as described in
‘Materials and Methods’ section. Cell viability was assessed with the MTT assay (A). Percentages
represent the ratio between the data for each condition and control (100%). Values indicate means and
s.e.m. from at least three experiments per group.NP-40 soluble fractions from rat E18 cerebral cortical
neurons treated as indicated were analyzed by western blotting (20 μg of protein/lane) (B) and probed
with the respective antibodies to assess the effect of the treatments on: Usp14 (panel 1), Tau cleaved at
Asp412, Tau (panel 2), caspase 3 (panel 3), level of ubiquitinated proteins (panel 4) and actin as loading
control (panel 4). Molecular mass markers in kDa are shown on the right.
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Figure 13C. Usp14 loss (Usp14axJ mouse) did not prevent the deleterious effects of PGJ2. Dissociated
cultures from homozygous Usp14axJ mice prepared as in [24] were treated as indicated. Loss of Usp14 in
the KO mice did not prevent activation of caspase-3 nor accumulation of Ub-proteins. Analysis in progress.
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2.5. DISCUSSION
In this study we characterize the mechanism(s) by which the Usp14 inhibitor IU1 affects
the ubiquitin/proteasome pathway (UPP) in rat cerebral cortical neurons. In non-neuronal cells,
IU1 is proposed to enhance the degradation of a range of proteasome substrates including Tau and
oxidized proteins [101], which are implicated in neurodegenerative disorders such as AD and PD.
Thus, it was critical to investigate the impact of IU1 on neurons.
We show that 75 µM IU1 prevented the accumulation of Ub-proteins induced by PGJ2 in
neurons, while IU1 concentrations 25 µM had no impact. IU1 (75 µM) was shown to reduce
menadione-induced accumulation of oxidized proteins in non-neuronal HEK293 cells [101]. Like
PGJ2 [108,115], the vitamin K analog menadione (K3) induces accumulation of Ub-proteins
[199,205]. However, whether or not IU1 blocks menadione-induced accumulation of Ub-proteins
was not addressed [101]. This is important, as non-aggregated Ub-proteins are turned over by the
26S proteasome, the activity of which is enhanced by inhibiting Usp14 with IU1 [101]. On the
other hand, most (70% to 80%) of all oxidized proteins that are not aggregated are degraded by
20S proteasomes in concert with immunoproteasomes [147]. The latter forms of the proteasome
do not associate with Usp14 and are not postulated to be affected by IU1 [101,146]. We discuss
the impact of IU1 on 20S proteasome activity in neurons below.
We also demonstrate that 75 µM IU1 induces calpain-dependent cleavage of endogenous
Tau, as Tau cleavage is blocked by a calpain inhibitor (calpeptin). This is further supported by the
finding that IU1-treatment clearly induces cleavage of -spectrin (280 kDa) to 145/150 kDa
fragments, which are indicative of calpain activation [197]. Moreover, the IU1-induced Tau
fragments include a typical “17 kDa” fragment, which represents a marker for enhanced calpain
activity in AD [46,55].
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Calpain-activation is linked to ATP-depletion and necrosis, a cell death pathway
characterized by a bioenergetic crisis [209]. It is well established that calpain-activation is induced
by mitochondrial inhibitors, such as oligomycin and antimycin [173]. Of relevance, we find that
the pattern of IU1-induced Tau cleavage in neurons resembles that observed in our previous studies
with these inhibitors [78]. In a similar manner, IU1 induced calpain-mediated cleavage of caspase
3 to a fragment (29 kDa) associated with caspase inactivation [78,143]. Calpain processing of
caspase 3 to the 29 kDa inactive form could be a strategy to prevent execution of the apoptotic
pathway under conditions of ATP-deficit, as apoptosis is an energy-dependent death pathway
[209]. Together these data show that IU1 (75 µM) treatment in neurons activates calpaindependent cleavage of Tau, spectrin and caspase 3, and suggest that IU1 may be neurotoxic and
diminish intracellular ATP levels.
We also establish that high IU1 concentrations (HIU1 25 µM) are significantly neurotoxic
as expected, since HIU1-treatment stimulated calpain-dependent cleavage of a range of substrates.
These findings suggest that HIU1-treatment induces cell death via necrosis and not apoptosis, since
it induces calpain and not caspase 3 activation. Furthermore, HIU1 (25 µM) concentrations cause
mitochondrial dysfunction reflected in significant decreases in intracellular ATP levels. Of
relevance, we show that IU1 inhibits mitochondrial Complex I in vitro. Taking into account the
high degree of flux control of mitochondrial Complex I over oxidative phosphorylation in neuronal
tissues [56,80,98], inhibition of even a small fraction of the enzyme, may lead to a significant
decrease in ATP production by mitochondria [192]. It cannot be excluded that IU1 inhibition of
NADH oxidation results in a change of redox state of the mitochondrial matrix leading to an
imbalance of ROS metabolism. PGJ2-treatment combined with IU1 exacerbated the detrimental
effects of IU1 on neuronal viability and ATP-level.
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We demonstrate that IU1-treatment (HIU1 >25 µM) impairs E1 and 26S proteasome
activities, both of which are ATP-dependent [44,114,167,188]. HIU1 hinders the ubiquitination
cascade by blocking its first step; i.e., HIU1 prevents ubiquitin-activation by the E1 enzyme,
without decreasing free Ub levels. The combined treatment with PGJ2 and IU1 exacerbated E1
dysfunction, compared to IU1 alone. Our data strongly support the view that IU1 prevents PGJ2induced accumulation of Ub-proteins, not by enhancing their turnover by the 26S proteasome, but
instead by blocking the ubiquitination cascade causing lower levels of Ub-proteins to be formed.
This would explain why proteasome substrates such as TDP-43 accumulate as ubiquitinated-TDP43 reflecting 26S proteasome inhibition (as discussed below), while little change was detected in
bulk ubiquitin conjugates in IU1-treated non-neuronal cells [101].
HIU1

elicited the demise of the 26S proteasome in neurons by diminishing its assembly,

which partially correlates with ATP-depletion. Concomitant with the decline in 26S proteasomes,
HIU1-treatment

induced a rise in the activity and levels of 20S proteasomes; that is HIU1 mimicked

the effects of mitochondrial inhibitors on proteasomal function, just as found for calpain-activation
and ATP-depletion [78]. We speculate that the significant increase in 20S proteasome activity
induced by HIU1-treatment, contributes to the reduction in menadione-induced accumulation of
oxidized proteins in HEK293 cells [101]. Menadione is a highly toxic oxidant that elevates
superoxide levels [50]. Upon ATP-depletion triggered by IU1-treatment it is possible that 20S
proteasomes are recruited to promote turnover of oxidized proteins independently of ubiquitination
[62,87]. Moreover, the 26S proteasome and the ubiquitination machinery are more vulnerable to
oxidative damage than 20S proteasomes [154]. Autophagy is not likely to be involved in the
degradation of menadione-induced oxidized proteins, as IU1 was shown to have no effect on
autophagy [74].
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As shown in the current studies, lowering Usp14 levels by siRNA or loss of Usp14
exhibited by neuronal cultures from Usp14axJ mice, did not counteract or exacerbate the
detrimental effects of PGJ2 on neurotoxicity, caspase 3-activation, caspase-dependent Tau
cleavage and accumulation of Ub-proteins. These results are in agreement with studies with HeLa
cells showing that siRNA for Usp14 alone had no effect on, for example, cell growth [94,96]. The
combined siRNA approach to knockdown Usp14 and another DUB UCH37, was necessary to
observe accumulation of Ub-proteins [94,96]. The functional relationship among multiple
deubiquitinases in terms of substrate hydrolysis and protein homeostasis, in particular in neurons,
requires further investigation.
Finally, we confirm that PGJ2 alone induces the accumulation of Ub-proteins, which is
consistent with previous studies showing that PGJ2 lowers 26S proteasome levels and activity
[81,124], and inhibits some of the thiol deubiquitinases including UCH-L1 and UCH-L3
[108,115], as well as Ub-isopeptidase activity [130]. We also show, for the first time, that PGJ2
lowers E1~Ub thioester levels. This result is surprising since we have shown that drugs that lower
E1~Ub thioester levels, such as IU1 (current study) and mitochondrial inhibitors [oligomycin and
antimycin in [78]] do not cause accumulation of Ub-proteins in neurons. It is likely that the
accumulation of Ub-proteins detected in PGJ2-treated neurons reflects its ability to inhibit
deubiquitinases that may stabilize the Ub-proteins formed prior to E1~Ub thioester depletion.
In summary, our findings show that IU1 is neurotoxic and lowers neuronal ATP levels by
inhibiting mitochondrial Complex I, leading to a decrease in E1~Ub thioester, Ub-protein, and 26S
proteasome levels, as well as calpain activation. In addition, pharmacologic (with IU1) or genetic
(with siRNA or by a spontaneous mutation in Usp14axJ mice) inhibition of Usp14 fails to protect
neurons against the detrimental effects of PGJ2. However, our data do not exclude the possibility
50

that inhibiting Usp14 (aside from IU1) is beneficial against other conditions that disturb protein
homeostasis. For example, inhibiting Usp14 with three specific RNA aptamers [single-stranded
synthetic RNA molecules that act like “chemical antibodies” [45]] facilitated the degradation of
Tau conditionally expressed in HeLa cells [103]. In agreement with our data, the latter study with
HeLa cells established that IU1 (~167µM) is significantly cytotoxic [103]. We also established
that neurons accumulate IU1 to a higher intracellular concentration than MEFs. Using mass
spectrometry we determined that neurons accumulate IU1 to ~90% of the extracellular
concentration, while MEFs were determined to accumulate IU1 to only 26% of the extracellular
concentration. The reason for this discrepancy remains to be established, but it may explain why
the neurons are more sensitive than the MEFs to IU1. In conclusion, due to the magnitude and
diversity of the enzymes involved in the UPP, a detailed understanding of their reaction
mechanisms and relationships in neurons is of the utmost therapeutic interest, since reducing the
levels of aberrant proteins in neurons is highly relevant to neurodegenerative disorders, such as
AD and PD [77].
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CHAPTER III

Infusion of the cyclooxygenase product of inflammation – Prostaglandin J2 into mouse hippocampi
induces AD-like pathology in an age-dependent manner
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3.1. ABSTRACT
Upregulation of cyclooxygenase-2 (COX-2) has emerged as an important determinant of
the cytotoxicity associated with neuroinflammation in AD. Prostaglandins (PGs) are major
products of cyclooxygenases, but their role in neurodegeneration is poorly understood. PGD2 is
the most abundant prostaglandin in the brain and increases the most under pathological conditions.
Specifically, cortical neurons in AD brains were shown to exhibit accelerated PGD2 synthesis.
PGD2 is unstable and is converted to the highly neurotoxic PGJ2 by spontaneous dehydration. In
preliminary studies to address the in vivo effects of PGJ2 we established a mouse model of
neuroinflammation relevant to AD. PGJ2 (16.7ug/2ul/week, for 3 weeks) was bilaterally
microinfused into the CA1 hippocampal brain region of aged (53 weeks of age) and young (12
weeks of age) mice. Following one week of post-surgery recovery, all mice underwent a 12-day
training period on the radial 8-arm maze (RAM) to assess spatial learning and memory. Our data
revealed significant spatial learning and long-term memory deficits in aged PGJ2-treated mice,
compared to the other three groups. Hippocampal Fluoro-Jade C staining identified a significant
increase in degeneration neurons in the CA3 region of aged PGJ2-treated mice, indicating a
progressive spread of damage from the site of injection to the adjacent sub-region. Golgiimmunohistochemical analysis identified a significant deficit in the expression of plasticity-related
spine types, stubby and filopodia, within CA1 dendrites of aged-PGJ2 treated mice compared to
the young-PGJ2 condition. This deficit occurred concomitantly with a significant increase in
colocalization of synaptic markers GluA2/PSD95 within these spine types, indicating a deficit in
maturation of spines via disrupted molecular trafficking and turnover. Our findings indicate that
PGJ2, as a product of inflammation, can initiate neurodegeneration as well as facilitate its
progression within the hippocampus in an age-dependent manner, thus mimicking processes that
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are highly relevant to AD pathology. We also assessed the efficacy of elevating endogenous cAMP
as a therapeutic intervention in our model. Accordingly, a group of aged mice received PGJ2
injections at the same time as PACAP27, a lipophilic neuroprotective peptide that raises
intracellular cAMP. PACAP27 treatment ameliorated PGJ2-mediated learning and memory
deficits on the RAM. We propose that this pre-clinical mouse model is highly valuable to identify
and optimize therapeutics that suppress the neurotoxic effects of inflammation as a strategy to
prevent or delay the progression of AD.
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3.2. INTRODUCTION
Neuroinflammation is a defense process activated upon CNS injury to initiate repair
mechanisms acutely, while chronic neuroinflammation can exacerbate, spread and prolong CNS
injury. Chronic neuroinflammation is implicated in a variety of neurological and
neurodegenerative disorders including AD [58,70,113]. Neuroinflammation is an active process
detectable in the earliest and latest stages of AD [110,204,207].
Cyclooxygenases (COX -1, constitutive and COX-2, inducible), which are key enzymes in
the conversion of arachidonic acid into bioactive prostaglandins (PGs) play a central role in the
inflammatory cascade. Inhibiting cyclooxygenases with non-steroidal anti-inflammatory drugs
(NSAIDs) is being explored as a therapeutic strategy to mitigate chronic neuroinflammation and
prevent the onset/progression of AD pathology [92,194]. NSAIDs’ effectiveness could be
compromised as they block the generation of all prostaglandin products of cyclooxygenases.
Prostaglandins act as potent local regulators of physiologic and pathologic pathways linked to CNS
inflammation. We focused our studies on PGJ2 because it is highly neurotoxic compared to PGA1,
D2 and E2 [108]. J2 prostaglandins including PGJ2, are endogenous toxic products of
cyclooxygenases actively involved in neuronal dysfunction [47].
PGJ2 is a product of spontaneous non-enzymatic dehydration of PGD2, which is the most
abundant prostaglandin in the brain [190], and undergoes the most changes under pathological
conditions [109]. Specifically, cortical neurons in AD brains were shown to exhibit accelerated
PGD2 synthesis [82] [202]. PGD2 is unstable as its half-life in the brain is 1.1 min and in the blood
0.9 min, and some of it is converted to PGJ2 [185]. In rodents, the in vivo concentration of free
PGJ2 in the brain upon injury such as stroke and TBI, increases from almost undetectable to the
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100nM range [115,116], which are levels shown to be neurotoxic in vitro [72,97].These
concentrations represent average brain levels, but local cellular and intracellular concentrations of
PGJ2 are potentially higher [117], as PGJ2 binds covalently to proteins [190]. Therefore free PGJ2
does not represent its total amounts.
PGJ2 signals in part via one of the PGD2 receptors, i.e. the DP2 receptor [68,126]. DP2 is
coupled to inhibitory G-proteins thus lowering cAMP [68], and we confirmed that PGJ2 indeed
lowers neuronal cAMP levels [124]. In an effort to overcome the cAMP deficit induced by PGJ2,
we showed that raising intracellular cAMP levels with PACAP overcomes some of the neurotoxic
effects of PGJ2 in rat cerebral cortical neuronal cultures [124], and in mice exhibiting
parkinsonian-like pathology upon microinfusion of PGJ2 into the substantia nigra [176].
PACAP27 is a lipophilic peptide that binds to the seven transmembrane G-coupled receptor
PAC1R (pituitary adenylate cyclase 1 receptor) at nanomolar levels, activating adenylate cyclase
and elevating cAMP [127]. PAC1R is expressed in the cerebral cortex and hippocampus as well
as other brain areas [88]. Overall, PACAP may offer a novel therapeutic approach to treat AD
because it not only ameliorates some of the pathological processes observed in AD models, but it
also diminishes some of the clinical symptoms of AD [203].
To examine the in vivo effects of PGJ2 relevant to AD, we microinfused PGJ2 into
hippocampi of aged (53 weeks of age) and young (12 weeks of age) mice. We included two
different age groups in our study because the single greatest risk of developing AD is aging [69],
with an exponential increase in cases after the age of 65 [15]. Moreover, steep age-related declines
in synaptic density and plasticity make the brain increasingly less efficient. Our findings indicate
that PGJ2, as a product of inflammation, can by itself initiate neurodegeneration as well as its
progression within the hippocampus in an age-dependent manner, mimicking pathology that is
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relevant to AD. Furthermore, PACAP27 diminished some of the memory deficits induced by
PGJ2. Like other toxic and genetic models, our new in vivo mouse model has limitations.
However, it provides a tool to test neuroprotective strategies with fewer undesirable side effects,
like PACAP27, applicable to AD and other neurodegenerative disorders in which the
cyclooxygenase pathway of inflammation is involved.
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3.3. MATERIALS AND METHODS
3.3.1. Materials - Drugs: PGJ2 (cat. # 18500, Cayman Chemical) in DMSO, and PACAP27
(pituitary adenylate cyclase-activating polypeptide, cat. # H-1172, Bachem Bioscience) in sterile
water. The final DMSO concentration in PBS was 17% for all microinfusions. The solutions were
freshly prepared and stored for a maximum of 2 h at 4 °C and in the dark.
Primary antibodies: GluA2, 1:1000 cat# MAB 397, EMD Millipore, PSD95, 1:1000, cat#
AB9708, EMD Millipore. Secondary antibodies: Alexa Fluor 568 (1:100, cat.# A11036, rabbit)
and Alexa Fluor 488 (1:100, cat.# A11029, mouse) both from Invitrogen. Vectashield Hard Set™
mounting medium with DAPI (cat.# H-1500, Vector Laboratories).
3.3.2. Mice - All procedures were performed in accordance with the NIH Guidelines for the Care
and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use
Committees at Hunter College. We included male B6-M (C57BL/6NTac) mice from Taconic
farms, ages - young (12 weeks of age) and aged (53 weeks of age), to mimic an aging paradigm.
Mice were singly housed on a 12h light/dark cycle with food and water available ad libitum, and
were habituated for one week before treatment. All mice were microinfused bilaterally into the
hippocampal CA1 region. Each mouse was injected once/week (Fig.14) with DMSO or PGJ2
(16.7μg in 2µl DMSO) for three weeks (3 total injections). After behavioral analyses, mice were
perfused and the brains removed and processed for immunohistochemical analysis.
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Figure 14. In vivo treatment and behavioral analysis outline. Groups of mice at two distinct ages (12 weeks and
53 weeks) were injected bilaterally with (16.7µg/2µl) of PGJ2 or DMSO into the CA1 region of the hippocampus.
Mice underwent radial 8-arm maze (RAM) training. 4 arms were baited/trial (*). There were 6 consecutive
trials/day.

3.3.3. Stereotaxic surgery - We followed the same procedures as described in our previous study
[148], except that mice received bilateral injections of vehicle (DMSO) or drugs (PGJ2 and
PACAP27) into the hippocampal CA1 subregion. Briefly, at the respective ages (12 weeks for the
young and 53 weeks for the middle-age), mice were anesthetized by isoflurane inhalation
(induction 2–2.5%, maintenance 1.5–2%) administered in 100% oxygen and placed into a
stereotaxic frame (Model 51730D, Stoelting Co., Wood Dale, IL) fitted with a gas anesthesia mask
(Model 50264, Stoelting Co.). A burr hole was drilled in the skull at coordinates relative to bregma
for the hippocampal CA1 subregion: rostral-caudal -2.0mm, medial-lateral +/- 1.0mm, dorsalventral +1.5mm, as specified in the mouse brain atlas [49]. A 2 μL microinjection Hamilton
syringe (7002 KH) with a 25-gauge needle was slowly inserted into the brain and left in place for
five minutes. Thereafter, 2 μL of solution was infused at an injection rate of 0.2 μL/min
(Quintessential stereotaxic injector, Model 53311, Stoelting Co.). The needle was left in place an
additional five minutes to ensure total diffusion of the solution. Following injection, the needle
was slowly removed and the incision was closed with monofilament absorbable sutures (cat. #
033899; Butler Schein Animal Health, Dublin, OH). After surgery, mice were administered a
subcutaneous injection of 0.5 cc Lactated Ringer's solution, given wet palatable rodent chow, and
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kept in a warm place to recover. Subsequent injections were administered via the same drill hole
established during the first surgical procedure.
3.3.4. Groups - Mice were randomly assigned to the treatment groups (Fig. 14). Mice in each age
group received three bilateral injections (once/week for three consecutive weeks) of DMSO/PBS
(n = 5 aged mice, n = 5 young mice) or PGJ2 (16.7μg in 2µl DMSO/PBS, n =5 aged mice, n = 4
young mice) per injection. To assess the therapeutic efficacy of PACAP27, groups of aged mice
received the same number of injections including PACAP27 (50 ng/2μL n =5), or
PACAP27 + PGJ2 (n = 6) and were compared to those mice that received DMSO or PGJ2 only.
3.3.5. The radial 8-arm maze (RAM) (Fig. 14) – RAM is a behavioral task used to evaluate longterm reference and short-term working memory simultaneously [168,170,171]. Briefly, mice were
food restricted to 85% of free-feeding weight. To acclimate mice to the maze prior to training each
mouse received three exposures/day (2 days) to the maze with all arms baited (10min intervals,
followed by 1h in home cage). During training, four of the 8 arms were baited with wet sweetened
oatmeal (Maypo Inc, NJ) as previously described [168,170,171]. The sequence of baited arms
remained fixed for each mouse. To avoid the use of internal maze cues, each day the maze was
rotated 90o keeping the position of the baited arms stationary with respect to the room cues. Mice
received 6 consecutive trials per day lasting no more than 3min per trial. To establish the trial %
correct score, we divided the number of food rewards collected by the total number of arms
entered. Reference and working memory errors were also scored. Reference memory errors occur
when a subject entered an arm that is never baited. Reference memory is also associated with longterm memory performance, thus the more correct arms entered during training, the better longterm memory the mouse has. Working memory errors were committed when a subject re-entered
an arm where the food reward had already been collected for that trial.
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3.3.6. Fluoro-Jade C analysis - Following behavioral analyses, mice were terminally anesthetized
(i.p.) with ketamine (100 mg/kg) and acepromazine (3 mg/kg), and transcardially perfused with
4% paraformaldehyde in PBS. The mouse brains were removed, post-fixed overnight at 4 °C,
followed by cryoprotection (30% sucrose/PBS at 4 °C). Brains were sectioned in the coronal plane
using a freezing microtome at a thickness of 20 μm, and sections were collected serially along the
rostrocaudal axis of the hippocampus. Tissue series were stored at 4 °C (TBS, pH7.4 plus 0.1%
sodium azide) until use. Each series was processed as free floating sections for Fluoro-Jade C
analysis. Degenerating neurons/terminals were detected with Fluoro-Jade C (cat# AG325,
Milipore) as described in [27,166].
3.3.7. Quantification - Fluoro-Jade analysis: Under a wide-field fluorescence microscope (Zeiss
AxioImager) the software AxioVision was used to capture whole hippocampal region mosaics
(MosaiX capture mode). Exposure time for channel was kept constant between sections. For each
captured image, ZVI files were load onto Image J (NIH, Bethesda, MD). Hippocampal subfields
were isolated, cropped, and saved as .tif files for use in intensity analysis Channel was thresholded
to extract the positive signal from all [150]. Pixel data above 75th percentile intensity were
measured for per square micron in each image crop.
3.3.8. Simultaneous Golgi-Cox Immunohistochemistry (GC-IHC) - Hippocampal brain
sections cut at a 50 µm were processed for GC-IHC (dendritic spines, GluA2, PSD95) as described
in [179]. LSCM (laser scanning confocal microscopy) with a Zeiss LSM 510 laser-scanning
confocal microscope and 3D analysis: Z-stacks (4-6 µm; Z-step size 0.041 µm for CA1) were
acquired of CA1 (15-75 µm in length, projecting into striatum radiatum). For 3D analysis, IMARIS
7.5 (Andor Technology; Belfast, Northern Ireland) was used to analyze spines, determine spine
morphology, and co-localize synaptic markers (PSD95 and GluA2) and dendritic structure.
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3.3.9. Statistics. All data are expressed as the mean ± SEM. Statistical analyses were performed
with GraphPad Prism 6 (GraphPad Software, San Diego, CA). A p-value < 0.05 was considered
statistically significant. For group comparisons, we performed one-way or two-way analysis of
variance (ANOVA) followed by post hoc Tukey or Bonferroni tests for multiple comparison.

3.4. RESULTS
3.4.1. PGJ2 delays spatial learning in aged compared to young mice - Previous data from our
lab with rat E18 cerebral cortical neuronal cultures showed that PGJ2-treatment causes AD-like
molecular pathological events, such as accumulation of ubiquitinated proteins, formation of ΔTau
which is the major component of neurofibrillary tangles, formation of Ub-protein aggregates, and
caspase-3 activation [124]. We were interested in investigating whether PGJ2 would induce ADlike behavioral deficits in an age-dependent manner in a mouse model.
We observed that aged (53 weeks of age) PGJ2-treated mice performed worse in the radial
arm maze (RAM) compared to the other 3 groups tested. The results obtained can be represented
as % correct arm entry, and reference memory errors. Reference memory error occurs when a
mouse enters an arm that is never baited. Behavioral analysis revealed that aged PGJ2-treated mice
scored the lowest amount of correct arms entry of all the 4 groups tested which translates into their
decreased learning and memory (Fig. 15 A and B). This correlates well with reference memory
error analysis. Aged PGJ2-treated mice had the highest number of reference memory errors
meaning that they entered arms that were never baited much more frequently than mice from the
other groups (Fig. 15 C and D). This suggests impairment in memory formation.
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There was no significant age difference in performance between DMSO-treated animals.
As shown in Fig. 15A mice injected with DMSO learned the radial arm maze (RAM) over 12 days
of training. Conversely young PGJ2-treated mice learned significantly better than aged PGJ2treated mice (Fig 15B). While all groups of mice showed significant improvement in their %
correct scores over training days, the aged PGJ2-treated mice appear to reach a lower level of
asymptotic performance at 65% correct. This learning deficit in aged PGJ2-treated mice is also
reflected in the reference memory errors (Fig.15C and D).
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Figure 15. PGJ2 delays spatial learning in old compared to young mice. (A) DMSO treated mice learn
equivalently showing a significant effect of training (F11,44 = 7.47, p < 0.001) without an effect of age. (B)
PGJ2-treated mice show a significant overall effect of training (F11,110 = 18.92, p < 0.001), age (F1,10 = 13.76,
p = 0.004), and a training by age interaction (F11,110 = 3.72, p < 0.001). Posthoc analysis for training days 1, 8,
11 and 12 showed significance (*p < 0.01). (C) Average Reference Memory Errors (RME) per trial were not
different between young and aged DMSO mice. (D) Aged PGJ2 mice averaged more Reference Memory
Errors (RME) per trial compared to young mice.

64

3.4.2. PGJ2 affects long-term memory retention in aged compared to young PGJ2-treated
mice - Long-term memory formation is known to be affected in AD patients. Therefore we
investigated if PGJ2 impaired memory retention in mice one week after completion of the 12 days
long training period. We found that PGJ2 impaired long-term memory in aged compared to young
mice. Six days after the last training trial all mice were given another 6 trials. The days average %
correct scores show that PGJ2-treated mice had significantly lower % correct scores than all other
groups (Fig. 16). These data reflect the behavioral traits of AD and its age-dependent vulnerability.

Aged

Young

Aged

RME

%Correct

Young

Figure 16. PGJ2 affects long-term memory in aged compared to young mice. Six days following the last
training, mice were given an additional 6 trials. (A) The % correct scores show a significant overall effect of
age (F

1,14

= 5.56, p = 0.03) and an age by drug interaction (F

1,14

= 7.56, p = 0.015), with no overall effect of drug

treatment. Post-hoc analysis showed significance (*p = 0.05). (B) Aged PgJ2-treated mice performed
significantly more reference memory errors compared to other groups tested.
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3.4.3. PGJ2 induces hippocampal damage that spans from CA1 to CA3 only in aged PGJ2treated mice - We next analyzed changes at the cellular level in the hippocampus. PGJ2 induced
a higher level of neurodegeneration in the hippocampus of aged compared to young mice as shown
with Fluoro-Jade C staining, which identifies degenerating neurons, glia and terminals (Fig. 17)
[27,166].

Aged-PGJ2

Young-PGJ2
Figure 17. PGJ2 induces hippocampal
damage that spans from CA1 to CA3 only
in aged mice. Fluoro-Jade staining analysis
(% DMSO) ran only on PGJ2 groups shows
an overall significant effect of subregion
CA1 vs CA3 (F

1,20

= 9.67, p = 0.006). No

significant age effect and a significant age by
subregion interaction (F

1,20

= 5.96, p = 0.02).

Significant posthoc analysis within CA3

Aged PGJ2
Aged DMSO

FJ-C (%DMSO)

Young PGJ2
Young DMSO
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subregion (*p<0.05) Scale bar, 100 µm.

3.4.4. PGJ2 induces dendritic spines defects in the hippocampal CA1 region of aged mice Dendritic spines are protrusions in post-synaptic compartments and are sites of synaptic
transmission. Each spine receives input from excitatory synapses and due to the presence of
neurotransmitter receptors, organelles and signaling cascades it has the ability to establish and
maintain the synapse. The presence of dendritic spines is linked to memory formation and defects
in their number and types are linked to memory deficits in various neural disorders, such as AD.
Spines are dynamic structures; their plasticity and remodeling are associated with learning. There
are four main types of spines, stubby, filopodia, long-thin and mushroom) (Fig. 18), characterized
by their developmental profile ranging from immature (stubby, filopodia) to mature (long-thin,
mushroom) [75,123].
B

A

C

D

Figure 18. Dendritic spine types and characteristics A, Spine types as characterized by [75]:
(Left to right) stubby, filopodia, long thin, and mushroom. Spines demonstrate a dynamic
developmental profile. Plastic, immature spines (stubby and filopodia) lack post-synaptic
density and AMPARs. Stable, mature spines (long-thin, mushroom) express higher levels of
synaptic markers. IMARIS XT parameters for spine detection using the spine classification
module. B, Parameters were based on relative spine neck and head relationships as in [12,124].
Representative Golgi-Cox IMHC dendrites for control conditions (scale bar = 5 μm for C; 3
μm for D. Golgi-Cox indicated in green, colocalization of synaptic markers in yellow. Red
arrowheads indicate long-thin spines, blue arrowheads indicate mushroom spines.
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The size of the spine head dictates whether the spine is immature and plastic or mature and stable.
Spines that have large mushroom-shaped heads are considered established, “memory” spines.
Characterizing spine morphology with Golgi-IHC is an innovative approach that allows the
coupling of immunohistochemistry with Golgi-Cox staining visualized with confocal microscopy
[179]. Our studies using this technique, identified a significant decrease in the total number of
dendritic spines in the hippocampal CA1 region of aged (Fig. 19 A) compared to young PGJ2treated mice. This result indicates deficits in memory and corroborates the findings of our
behavioral analyses. Moreover, aged PGJ2-treated mice have less stubby and filopodia spines in
the CA1 dendrites (Fig. 19 B and C), suggesting that PGJ2 impaired spine plasticity that could
lead to learning and memory deficits.
A

Average spines /micron

Total spines

Figure 19 (A). Dendritic spine analysis. Using a Leitz
Diaplan microscope, a Nikon DXM 1200F camera, and
Image Pro Plus software (Media Cybernetics, Bethesda,
MD, USA), dendritic spine density on pyramidal cells from
the CA1 region of the dorsal hippocampus and layer II/III
of the mPFC were analyzed. Regions were defined based
on The Mouse Brain in Stereotaxic Coordinates (Franklin
KBJ, Paxinos G: 1997) and counting was done as described
by Frankfurt et al (Dev Neurosci. 2009;31(1-2):71-5).
Images of tertiary dendrites projecting into the stratum
radiatum of CA1 (15-95 μm in length) and in CA3 (20-95
μm in length) were captured using a Leica SP2 confocal
microscope. Spine morphology and expression of synaptic
proteins were then quantified using IMARIS filament
tracer.
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B

Young PGJ2

C

Aged PGJ2

Young PGJ2

Average spines /micron

Average spines /micron

Aged PGJ2

Figure 19. Dendritic spine analysis. (B) Aged-PGJ2 treated mice display significantly less plastic spines
(stubby and filopodia), (C) Aged-PGJ2-treated mice display less mature spine types than young PGJ2-treated
mice but this change is not statistically significant

Mature spines have well established post-synaptic densities (PSD), which are zones close
to the membrane that consists of neurotransmitter receptors, channels and systems involved in
synaptic transmission (Fig. 20). One of the markers of a fully developed, mature spine is PSD95,
a scaffold protein that determines structural and functional integrity of excitatory synapses [16].
The other marker is GluA2, a subunit of an AMPA glutamate receptor which is critical for synaptic
plasticity. We assessed the levels of both of these synaptic markers because their co-localization at
the post-synaptic terminal labels an active, mature synapse associated with formed memories. Our
analysis revealed increased levels of GluA2 and PSD95 in stubby (immature) spines in the CA1
region of aged compared to young PGJ2-treated mice (Fig. 20). This unexpectedly high level of
mature synaptic markers in plastic spines may indicate disrupted protein trafficking resulting in
their inability to mature into memory-associated spines, i.e. long-thin and mushroom types, which
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can explain memory deficits in vivo.
Young PGJ2

B

*

GluA

A

B

*

PSD9

Aged PGJ2

Average

Average Voxels/micron

A

Average Voxels/micron

C

*

C

Co-localization

Figure 20. IHC analysis of dendritic spines (A) GluA2 and (B) PSD95 levels are significantly
increased in stubby spines in aged PGJ-treated mice. (C) Significantly increased colocalization of
GluA2 and PSD95 in stubby spines in aged PGJ2-treated mice. (D) Representative Golgi-Cox IMHC
dendrites for control conditions (scale bar = 5 μm. Golgi-Cox indicated in green, co-localization of
synaptic markers in yellow.
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3.4.5. PACAP27 prevents learning and memory deficits induced by PGJ2 in aged mice.
We investigated if neuroprotective peptide PACAP27 could prevent learning and memory
retention loss in PGJ2-treated mice (Fig. 21). PACAP did prevent learning deficits in aged PGJ2treated mice to a certain extent. The % correct arm entry was higher for aged PGJ2/PACAP-treated
mice from day 3 to day 12 of RAM training than PGJ2-treated mice. On day 9 the difference
between the two groups was statistically significant (p value = 0.0107). Aged mice injected with
PACAP alone did not perform significantly different from aged mice injected with Vehicle
(DMSO).
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Aged PGJ2
PACAP+PGJ2
Aged
Aged PGJ2
%Correct (Av/Day)

%Correct (Av/Day)

Aged PACAP
Aged DMSO

Training day
%Correct (Av/Day)

%Correct (Av/Day)

Training day

Figure 21. PACAP27 prevents learning and memory deficits induced by PGJ2 in
aged mice. Mice underwent 12 day learning period on RAM. %correct arm entries for
all the mice from all cohorts on a particular day was averaged as represented in (A)
and (B). 6 days after completing last training, mice were subjected to additional 6 trials
and their performance from that day is represented in (C) and (D)
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DISCUSSION
One of the earliest clinical hallmarks of AD is progressive memory impairment. Patients
suffering from this debilitating condition exhibit loss of spatial memory and are unable to orient
themselves with respect to physical surroundings. This memory symptom correlates with neuronal
death in the hippocampus, the brain region responsible for learning, spatial orientation and memory
storage. AD-relevant memory loss can be recapitulated in mouse models and is easily examined
as there are numerous, well established behavioral assays available to test memory in rodents.
Studies showed that a lesion in hippocampal CA1 region in rats is sufficient to produce memory
impairment [84]. The causes of initial pathology of AD are not yet understood but there is
consensus in the scientific community that chronic neuroinflammation plays and important role in
neurodegeneration.
We focused our investigations on the product of inflammation PGJ2 because it is highly
neurotoxic [108], and its levels have been shown to increase upon pro-inflammatory stimuli such
as brain injury (ex. stroke and TBI) [97],[72], which is a well-established risk factor for AD. Our
preliminary studies indicate that microinfusion of the cyclooxygenase product of inflammation
PGJ2 into the CA1 region of the hippocampus initiates neurodegeneration as well as its
progression within the hippocampus in an age-dependent manner, thus mimicking pathology that
are highly relevant to AD.
As memory and cognitive impairment are central problems in AD, we used behavioral tests
to characterize spatial learning and memory deficits induced by PGJ2 over time in aged (53 weeks
of age) and young (12weeks of age) mice. Our preliminary studies show that PGJ2 impaired longterm memory in aged compared to young mice. Moreover, PGJ2 induced neurodegeneration in the
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hippocampus of aged mice compared to young mice as shown with Fluoro-Jade C staining. PGJ2
also decreased synaptic plasticity in aged mice, which could explain learning impairment. The
behavioral deficits induced by PGJ2 were correlated with the colocalization of specific synaptic
markers within various spine types. Trafficking of the GluA2 receptor subunits to the postsynaptic
density increases during episodes of synaptic plasticity, and stabilizing AMPA receptors within
the synaptic membrane is important for memory consolidation [169]. Our analysis revealed that
GluA2 (subunit of the AMPA receptor) as well as PSD95 (postsynaptic density marker) were both
significantly higher in the stubby spines of aged-PGJ2 treated mice. This novel finding could
indicate that PGJ2 impairs the ability of plastic spines to mature into memory associated spines,
resulting in memory deficits in-vivo.
We also showed that the neuroprotective peptide PACAP27 prevented to a certain extent
learning and memory impairment induced by PGJ2 in aged mice. These studies require further
analysis, for example assessing whether PACAP could prevent PGJ2-induced neurodegeneration
as well as dendritic spine deficiencies. Overall, our data indicate that targeting PGJ2 by increasing
cAMP levels with PACAP27 may be an efficient therapeutic approach to prevent PGJ2-dependent
neurodegeneration and memory deficits.
Our investigation of the neurotoxic pathway and mechanisms by which PGJ2 leads to
neurodegeneration underscores its relevance as a risk factor mediating the long-term effects of
neuroinflammation in the progression to AD. Targeting factors downstream of cyclooxygenases,
such as PGJ2, offer great promise as a new therapeutic strategy that would not alter the homeostatic
balance offered by cyclooxygenase derived prostaglandins.
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CHAPTER IV

CONCLUSIONS
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Sporadic Alzheimer’s disease (sAD) is an age-related neurodegenerative disorder. Its
causes are largely unknown but evidence supports that a combination of environmental and
lifestyle factors can cause recurring inflammatory insults that contribute to chronic
neuroinflammation and neuronal death. Despite decades of research it is still not known how to
prevent, slow down or cure AD. Medicine that is currently available for AD patients offers only
temporary, symptomatic relief [52]. Current research on AD focuses on developing new imaging
tools that facilitate detection of pathological changes in the brain early enough to start treatment
that would prevent neurodegeneration [87]. Another research focus is on developing new
therapeutic strategies. These two areas of investigation need to go hand in hand for advancement
and efficient treatment of AD.
UPP is essential for maintaining cellular homeostasis as it is involved in a number of
cellular processes, such as neuronal homeostasis, synaptic plasticity, signal transduction, and
mitochondrial dynamics. Impairment of this proteolytic pathway has long been associated with
AD. Agents that increase the efficacy of the UPP could improve proteasomal function and prevent
accumulation and aggregation of Ub-proteins, both of which are hallmarks of AD.
Our studies focused on examining two new potential therapeutic targets related to the UPP:
a) The Usp14 deubiquitinating enzyme – we investigated whether its inhibition
increases proteasome-dependent degradation and decreases toxicity induced by the
endogenous product of inflammation PGJ2.
b) The product of inflammation PGJ2 that impairs different steps of the UPP – we
investigated whether PGJ2 induces AD-like neuronal and behavioral pathology in vivo, by
microinfusing it into hippocampi of young and aged mice. In addition, we determined the
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potential of PACAP to overcome the deleterious effects of PGJ2.
a) Studies with the Usp14 deubiquitinating enzyme:
We attempted to increase proteasome-dependent degradation by inhibiting the Usp14
enzyme using pharmacological and genetic approaches. The Usp14 deubiquitinating enzyme
slows down protein degradation by removing ubiquitin tags too soon, allowing the substrate to
prematurely dissociate from proteasomes thus avoid degradation. Studies from other groups
showed that inhibiting Usp14 in MEFs and HEK cells with the small molecule inhibitor IU1
increased the degradation of proteasome substrates implicated in neurodegenerative diseases, such
as Tau, TDP-43 and ataxin-3 [101]. In our studies, we investigated the effects of IU1 on rat E18
cerebral cortical neuronal cultures, a cell model that is much more physiologically relevant to AD
than MEFs or cancer cell lines such as HEK cells. Treatment of primary neurons with high
concentration of IU1 (75 µM) decreased the levels of Ub-proteins induced by PGJ2, suggesting
that inhibiting Usp14 with IU1 indeed enhanced Ub-protein degradation and prevented their
accumulation. However, this result was accompanied by other thought provoking data. Our studies
showed that IU1 (75 µM) treatment in neurons activates calpain-dependent cleavage of Tau,
spectrin and caspase-3 and decreases the levels of 26S proteasomes with a concomitant increase
in 20S proteasomes. These findings suggested that IU1 could have off target effects. We confirmed
this by demonstrating that IU1 inhibits mitochondrial complex 1 leading to mitochondrial
impairment and ATP deficits. In addition, we established that Usp14 knockdown by siRNA in rat
neuronal cultures, or Usp14 loss in Usp14axJ mouse neuronal cultures did not change the levels of
Ub-proteins induced by PGJ2. These data strongly support the view that IU1 prevents PGJ2induced accumulation of Ub-proteins, not by enhancing their turnover by the 26S proteasome, but
instead by blocking the ubiquitination cascade causing lower levels of Ub-proteins to be formed.
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While our studies focused on investigating the properties of a new potential therapeutic,
we had another unexpected finding. We showed, for the first time to our knowledge, that PGJ2
lowers E1~Ub thioester levels. This result is surprising since we have shown that drugs that lower
E1~Ub thioester levels, such as IU1 (current study) and mitochondrial inhibitors (oligomycin and
antimycin in [78]) do not cause accumulation of Ub-proteins in neurons. It is likely that the
accumulation of Ub-proteins detected in PGJ2-treated neurons reflects its ability to inhibit
deubiquitinases that may stabilize the Ub-proteins formed prior to E1~Ub thioester depletion.
In conclusion, the functional relationship between the enzymes and components of UPP
requires further investigation as detailed understanding of their interactions are of the utmost
therapeutic interest since reducing the levels of aberrant proteins in neurons is highly relevant to
neurodegenerative disorders, such as AD.
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b) Studies with the product of inflammation PGJ2 that impairs different steps of the UPP.
Chronic inflammation is emerging as a major factor involved in AD pathogenesis and its
progression. Chronic inflammation is manifested by activated microglia and astrocytes that release
neuroprotective and neurotoxic factors. Some of these factors are produced by cyclooxygenases,
key enzymes in the conversion of arachidonic acid into prostaglandins. Our previous studies
showed that PGJ2 is a highly toxic product of COX-2 [108], the levels of which increase upon
brain injury and during neurodegeneration [110],[7].

PGJ2 belongs to the cyclopentenone

prostaglandin family. These PGs are unique in that they form covalent Michael adducts by binding
to free sulfhydryl groups on proteins thus modifying them and potentially impairing their structure
and function. This pathogenic process can contribute to neurodegeneration, in particular because
PGJ2 impairs the UPP by different mechanisms, such as inhibiting UCH-L1 the most abundant
deubiquitinating enzyme in the brain, as well as disrupting 26S proteasome assembly [198].
Epidemiological studies suggest that patients taking non-steroidal anti-inflammatory drugs
(NSAIDs) are at a reduced risk (by as much as 50%) for developing AD, although this notion is
controversial. NSAIDs target cyclooxygenases thus inhibit formation of all downstream
prostaglandins including neuroprotective ones. Additionally, inhibiting COX-1 and COX-2 was
shown to have side effects such as renal failure and stroke [140]. Therefore, we postulated that
taking a more directed approach and targeting PGJ2, a neurotoxic prostaglandin that is downstream
of COX-2 would be of more benefit.
To test this hypothesis PGJ2 (16.7μg in 2µl/week, for 3 weeks) was bilaterally
microinfused into the CA1 hippocampal region of aged (53 weeks) and young (12 weeks) mice.
Our preliminary data established that PGJ2-treatment caused a) memory deficits, b) degeneration
that spanned from the CA1 to the CA3 region of the hippocampus, and c) dendritic spine defects
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in the CA1 region. We also found that these pathological changes were age-dependent being
detected in aged but not young PGJ2-treated mice. These results strongly support the view that
PGJ2 by itself is sufficient to induce AD-like neuronal and behavioral pathology, and suggest that
inhibiting its activity would be a beneficial therapeutic approach. The benefit lays in the fact that
expression of other neuroprotective prostaglandins would not be affected by this approach, and
perhaps side effects stemming from prolonged usage of NSAIDs could be avoided.
Our in vivo studies with PGJ2 are very promising but we still need to address other
potential mechanisms by which PGJ2 disturbs neuronal homeostasis to broaden our understanding
of the impact that inflammation has on the brain (discussed in Future Directions). In addition, our
studies could contribute to developing an AD model of inflammation that could serve as a platform
for testing neuroprotective drugs. To this end, we concluded our studies with briefly testing the
neuroprotective peptide, PACAP27 as a potential therapeutic for AD. We demonstrated that coadministration of PACAP27 and PGJ2 mitigates some memory impairment induced by PGJ2
treatment, although this change is not statistically significant. PGJ2 signals via the DP2 receptor,
which is coupled to inhibitory G proteins that lower intracellular cAMP [68], [76], [126]. We and
others previously demonstrated that PACAP treatment of neuronal cultures overcomes the
decrease in cAMP levels induced by PGJ2 [124], [178]. This approach requires further
investigation to assess whether PACAP27 protects against PGJ2-induced neurotoxicity.
In conclusion, the potential therapeutic strategies we investigated here offer new insights
into mechanisms of AD development and if further explored could potentially prevent
neurodegeneration in AD.
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Figure 23. Model 2. PGJ2 as a potential therapeutic target in AD model of inflammation
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CHAPTER V

FUTURE DIRECTIONS
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Many neurodegenerative disorders, including AD are related to the abnormal accumulation
of symptomatic proteins. For example in AD it is truncated Tau – ΔTau - that is deposited in
neurofibrillary tangles. A decrease in protein turnover is associated with impaired UPP.
Maintaining protein homeostasis presents a critical task in post-mitotic neuronal cells. Therefore,
developing new strategies aimed at enhancing or preserving the function of the UPP as well
preventing neurotoxicity is essential for substantial therapeutic efficacy.
Inhibiting Usp14 was not effective in our cell model, i.e. rat E18 cerebral cortical neuronal
cultures. Moreover, other investigators showed that Usp14 null mice (ataxia mice) exhibit
developmental abnormalities including motor impairment, reduced brain mass and death by 2
months of age [25]. This proves that targeting any component of such a complex pathway like the
UPP requires detailed knowledge of its function and understanding of its interactions with other
elements. Furthermore, the small molecule inhibitor of Usp14, i.e. IU1, turned out to have an offtarget effect by inhibiting mitochondrial complex 1 thereby causing mitochondrial impairment and
ATP deficits. Since many exogenous, small molecules have off-target effects that are difficult to
predict we suggest employing other strategies.
We propose the following:
1)

Investigate increasing UPP function and preventing neurotoxicity by using

neuroprotective peptides - Perhaps endogenous, neuroprotective peptides could be a better
choice of potential therapeutics as unpredictable off-target effect would be avoided. Additionally
a combination therapy involving more than one peptide could act in a variety of ways to prevent
AD-related neurodegeneration. Studies from our group previously showed that one such peptide,
PACAP27, diminishes PGJ2-induced toxicity in rat E18 cerebral cortical neuronal cultures via
activating cAMP/PKA pathway. Conversely, PGJ2 was shown to decrease cAMP [124].
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PACAP27 decreased caspase-3 activation, ΔTau formation, Ub-proteins levels and aggregation,
and the loss of cell viability [124]. PACAP27 was also shown to be protective in vivo
[30,32,36,42]. Overall, PACAP27 appears to be a good therapeutic as it alleviates many of the
symptoms induced in our cell model of inflammation. However, AD is a multifactorial disease, so
combining PACAP with other protective peptides that exert different functions could be of greater
benefit. Another potential therapeutic, (VEGF) is a vascular endothelial growth factor that
promotes angiogenesis and neurogenesis both in vivo and in vitro [86,102,120]. VEGF's potential
as a protective factor has been demonstrated in hypoxia–ischemia, in vitro excitotoxicity, and
motor neuron degeneration [184], [182]. There are a number of neuroprotective peptides that could
be explored such as AdNP (activity-dependent neuroprotective protein), which is a glial cell
modulator of VIP associated neuroprotection and is implicated in maintenance of cell survival
through modulation of p53 expression ([8], [177,208]). AIP (autocamtide-related inhibitory
peptide) was shown to inhibit Ca2+/Calmodulin dependent protein kinase II, Aβ-triggered
activation of caspase 2 and 3, and Tau phosphorylation, as well as protect neurons against Aβ
toxicity [111]. Patients with AD show a marked loss of cholinergic neurons and diminished
Substance P expression [149]. Substance P is a short peptide that interacts with the cholinergic
ascending system resulting in enhancement effects [1]. In conclusion, there are a number of
endogenous neuroprotective peptides the levels of which are decreased in AD. They act in different
ways and in different pathways. Therefore increasing their levels and using them in combination
could be of great therapeutic value.

84

2)

Our studies would benefit from more detailed evaluation of PGJ2 toxicity in

vivo. We propose to:
a) Assess if PGJ2 causes microglia activation in hippocampus. Activated microglia
are a hallmark of inflammation, therefore assessing their level of activation would allow us to
determine if PGJ2 administration exacerbates the immune response in the hippocampus. It would
also allow us to investigate whether age exacerbates PGJ2-induced microglial activation. This
would be carried-out by IHC analysis using IBA-1 as an activated microglia marker.
b) Assess if PGJ2 induces caspase-dependent Tau cleavage and leads to the
formation of ΔTau. Tau is a microtubule associated protein the function of which is to stabilize
microtubules. However, during AD-related neurodegeneration it becomes hyperphosphorylated
and cleaved by activated caspases 3 and 8 to aggregation-prone ΔTau which is a major component
of neurofibrillary tangles. We previously showed that this is the case in rat E18 cerebral cortical
neuronal cultures treated with PGJ2 [124]. It would be interesting to investigate whether PGJ2
induces caspase activation and caspase-dependent Tau cleavage to ΔTau in our PGJ2-induced
mouse model of neuroinflammation that exhibits AD-like pathology.
c) Investigate if PGJ2-induced pathology could be prevented by delivering
PACAP in vivo. We have already determined that PACAP co-injected with PGJ2 improves
learning in aged mice, although this change is not statistically significant. It would be interesting
to investigate if PACAP could prevent molecular and cellular pathological changes induced by
bilateral injections of PGJ2 into the CA1 region of the hippocampus. We would assess microglial
activation, degeneration, dendritic spines abnormalities and other parameters. The next step would
be to administer PACAP27 intranasally to mice that have been previously injected with PGJ2. The
intranasal route of administration is an established procedure and has been exploited by numerous
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investigators to successfully deliver a variety of therapeutics, like neurotrophic factors [185,191],
cytokines [160,206], and neuropeptides [6]. Most importantly, intranasal delivery of PACAP has
been shown to reduce β-amyloid plaques in an AD transgenic mouse model [152]. Intranasal
delivery of therapeutics to the central nervous system (CNS) has the advantage that it bypasses the
blood brain barrier (BBB) and systemic adversities [66]. Drugs get absorbed through the nasal
mucosa and reach CNS via three potential pathways:

a) adsorptive or receptor-mediated

endocytosis into olfactory sensory neurons (OSNs) followed by intracellular transport to the
olfactory bulb; b) non-specific fluid phase endocytosis into OSNs followed by intracellular
transport into the olfactory bulb; c) extracellular diffusion along the open inter-olfactory clefts
directly to the olfactory bulb, then to the subarachnoid space and cerebrospinal fluid (CSF) [66]
[34]. From the cerebrospinal fluid drugs are distributed throughout the brain. Overall, intranasal
delivery of PACAP provides a promising alternative to other routes of administration and is
physiologically relevant, since a direct pathway exists between the olfactory epithelium and the
brain.
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